WO2014005721A1 - Use of (r)-phenylpiracetam for the treatment of parkinson's disease - Google Patents
Use of (r)-phenylpiracetam for the treatment of parkinson's disease Download PDFInfo
- Publication number
- WO2014005721A1 WO2014005721A1 PCT/EP2013/001991 EP2013001991W WO2014005721A1 WO 2014005721 A1 WO2014005721 A1 WO 2014005721A1 EP 2013001991 W EP2013001991 W EP 2013001991W WO 2014005721 A1 WO2014005721 A1 WO 2014005721A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenylpiracetam
- agent
- treatment
- parkinson
- fatigue
- Prior art date
Links
- LYONXVJRBWWGQO-JTQLQIEISA-N 2-[(4r)-2-oxo-4-phenylpyrrolidin-1-yl]acetamide Chemical compound C1C(=O)N(CC(=O)N)C[C@H]1C1=CC=CC=C1 LYONXVJRBWWGQO-JTQLQIEISA-N 0.000 title claims abstract description 154
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 80
- 238000011282 treatment Methods 0.000 title claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 206010016256 fatigue Diseases 0.000 claims description 86
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 55
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 238000011284 combination treatment Methods 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 18
- 208000019914 Mental Fatigue Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 239000008177 pharmaceutical agent Substances 0.000 claims description 14
- 238000009256 replacement therapy Methods 0.000 claims description 12
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 9
- 229960000911 benserazide Drugs 0.000 claims description 8
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 6
- 229960003089 pramipexole Drugs 0.000 claims description 5
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims description 5
- 229960000245 rasagiline Drugs 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229960004205 carbidopa Drugs 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 4
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 claims description 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 3
- 229940052760 dopamine agonists Drugs 0.000 claims description 3
- 229950006047 eltoprazine Drugs 0.000 claims description 3
- WVLHGCRWEHCIOT-UHFFFAOYSA-N eltoprazine Chemical compound C1CNCCN1C1=CC=CC2=C1OCCO2 WVLHGCRWEHCIOT-UHFFFAOYSA-N 0.000 claims description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 description 57
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 51
- 241001465754 Metazoa Species 0.000 description 47
- 238000012360 testing method Methods 0.000 description 45
- 229960004502 levodopa Drugs 0.000 description 42
- LYONXVJRBWWGQO-UHFFFAOYSA-N 2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide Chemical compound C1C(=O)N(CC(=O)N)CC1C1=CC=CC=C1 LYONXVJRBWWGQO-UHFFFAOYSA-N 0.000 description 38
- 239000003814 drug Substances 0.000 description 30
- 241000700159 Rattus Species 0.000 description 29
- 210000004556 brain Anatomy 0.000 description 28
- 229940079593 drug Drugs 0.000 description 26
- 229960003638 dopamine Drugs 0.000 description 25
- 208000012661 Dyskinesia Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 201000010099 disease Diseases 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 235000013305 food Nutrition 0.000 description 16
- 238000001690 micro-dialysis Methods 0.000 description 15
- 238000007912 intraperitoneal administration Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000006742 locomotor activity Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 208000006083 Hypokinesia Diseases 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 230000008450 motivation Effects 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 238000013222 sprague-dawley male rat Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000000648 anti-parkinson Effects 0.000 description 7
- 239000000939 antiparkinson agent Substances 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 238000000537 electroencephalography Methods 0.000 description 7
- 230000003483 hypokinetic effect Effects 0.000 description 7
- 210000001577 neostriatum Anatomy 0.000 description 7
- 239000002664 nootropic agent Substances 0.000 description 7
- 230000001777 nootropic effect Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 229960003878 haloperidol Drugs 0.000 description 6
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 229940025084 amphetamine Drugs 0.000 description 5
- -1 fenotropyl Chemical compound 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000003447 ipsilateral effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 4
- 206010034010 Parkinsonism Diseases 0.000 description 4
- 229920005439 Perspex® Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000002929 anti-fatigue Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229960001344 methylphenidate Drugs 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000004926 polymethyl methacrylate Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- SFLSHLFXELFNJZ-CMIMLBRMSA-N 4-[(1r)-2-amino-1-hydroxy-1-tritioethyl]benzene-1,2-diol Chemical compound NC[C@@](O)([3H])C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-CMIMLBRMSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000016253 exhaustion Diseases 0.000 description 3
- 210000005153 frontal cortex Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000004189 reticular formation Anatomy 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000002636 symptomatic treatment Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229920009441 perflouroethylene propylene Polymers 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000018299 prostration Diseases 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 229940015297 1-octanesulfonic acid Drugs 0.000 description 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- BBACKDMGYMXYLE-UHFFFAOYSA-N 3-thiophen-2-ylpiperazin-2-one Chemical compound O=C1NCCNC1C1=CC=CS1 BBACKDMGYMXYLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GXHZJFOEDFUGMK-UHFFFAOYSA-N 6,6-dimethyl-2-(2-phenylethynyl)-7,8-dihydroquinolin-5-one Chemical compound C=1C=C2C(=O)C(C)(C)CCC2=NC=1C#CC1=CC=CC=C1 GXHZJFOEDFUGMK-UHFFFAOYSA-N 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 238000001282 Kruskal–Wallis one-way analysis of variance Methods 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 238000006229 Nazarov cyclization reaction Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000012721 SDS lysis buffer Substances 0.000 description 1
- 241001116459 Sequoia Species 0.000 description 1
- 101710114615 Sodium-dependent dopamine transporter Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000364021 Tulsa Species 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 230000002891 anorexigenic effect Effects 0.000 description 1
- 230000003496 anti-amnesic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229960001335 benserazide hydrochloride Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 239000002475 cognitive enhancer Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000632 dystonic effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000010006 flight Effects 0.000 description 1
- 229950006364 fonturacetam Drugs 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000028270 inhibition of dopamine uptake Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004245 medial forebrain bundle Anatomy 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- WUOSYUHCXLQPQJ-UHFFFAOYSA-N n-(3-chlorophenyl)-n-methylacetamide Chemical compound CC(=O)N(C)C1=CC=CC(Cl)=C1 WUOSYUHCXLQPQJ-UHFFFAOYSA-N 0.000 description 1
- 229940126662 negative allosteric modulator Drugs 0.000 description 1
- 230000004776 neurological deficiency Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 208000008016 pathologic nystagmus Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229960003389 pramiracetam Drugs 0.000 description 1
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008307 presynaptic mechanism Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000009570 retrograde amnesia Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960001957 stomatological preparations Drugs 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229950004600 tenilsetam Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003569 transporter assay Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010153 Šidák test Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Definitions
- the present invention relates to the efficient treatment of an individual afflicted with Parkinson's disease (PD), the instant treatment comprising administering to the individual an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
- PD Parkinson's disease
- This invention relates to a method of treating patients afflicted with Parkinson's disease.
- Parkinson's disease is one of the most common chronic neurological diseases.
- the classical symptoms of PD are characterized by slowness of movement (bradykinesia/akinesia), rigidity and/or tremor.
- These symptoms may have an idiopathic, toxic, traumatic or genetic origin (e.g. , in Parkinson's disease (PD)) or may also occur as a consequence of treatment, e.g., with dopamine receptor antagonists in schizophrenia (Parkinson syndrome).
- Parkinson's disease is one of the most common chronic neurological diseases.
- the classical symptoms of PD are characterized by slowness of movement (bradykinesia/akinesia), rigidity and/or tremor.
- These symptoms may have an idiopathic, toxic, traumatic or genetic origin (e.g. , in Parkinson's disease (PD)) or may also occur as a consequence of treatment, e.g., with dopamine receptor antagonists in schizophrenia (Parkinson syndrome).
- Parkinson's disease is one of the
- L-DOPA levodopa
- Pamipexol dopamine receptor agonists
- non-motor symptoms are autonomic dysfunctions (cardiovascular, urinary and gastrointestinal), sleep problems, psychosis, pain, cognitive deficits and fatigue.
- autonomic dysfunctions cardiac, urinary and gastrointestinal
- sleep problems sleep problems
- psychosis psychosis
- pain cognitive deficits
- fatigue and depression have the strongest association with a decline in the quality of PD patients' life (Beiske et al., Mov Disord. 25, 2456-60, 2010; Beiske and Svensson, Acta Neurol Scand Suppl.190, 78-81 , 2010).
- Fatigue in PD is multidimensional including physical, mental and general aspects (Havlikova et al., Parkinsonism Relat Disord.14, 187-192, 2008; Havlikova et al., Eur J Neurol. 15, 475-80, 2008; Havlikova et al., J Neurol Sci. 270, 107-1 13, 2008).
- the physical dimensions of fatigue in PD are connected to problems regarding mobility and activity of daily living.
- Mental fatigue dimensions affect cognition, motivation, emotional well-being, and communication.
- general fatigue is related to bodily discomfort of the patients.
- Fatigue associated with Parkinson's disease has to be differentiated from fatigue symptoms in healthy individuals, where fatigue is a normal result of a natural reaction of body and mind to long-lasting and/or heavy burden, working, mental stress, over-stimulation or under-stimulation, jet lag, boredom, or lack of sleep.
- the physiological fatigue in healthy individuals is a normal response to physical exertion or stress, and its function is simply to protect the body from damage by overcharge.
- Such type of fatigue normally disappears spontaneously after a short recovery period. This type of fatigue isn't pathological and needs no therapeutic intervention. It is excluded from the intended medical use of the present invention.
- Only the pathological disease-oriented type of fatigue is targeted by the present invention, and, unless otherwise defined, the term "fatigue" as used herein stands for the pathological form only.
- FSS Fatigue Severity Scale
- Krupp et al. Arch Neurol. 46, 1 121-1 123, 1989.
- Each item has to be rated on a seven-grade Likert scale with a range from 1 (completely disagree) to 7 (completely agree), see Table 1.
- the total FSS score is mean score of the scores on respective 9 items.
- a total FSS score of 4 or higher present over 2 weeks prior to scoring is accepted as definition of presence of disease-oriented fatigue, especially in chronic diseases, e.g. Parkinson's disease.
- Karabanov et al. describe an open-label study of the effects of phenylpiracetam on patients suffering from PD (Karabanov et al., Atmosfera. Nervnye Bolezni 4, 29-32, 2009). In the study report, it is mentioned that fatigue was one of the parameters being monitored in the study, and a figure is presented showing a positive effect of phenylpiracetam on the combined parameter "general activity, physical and mental fatigue, asthenization symptoms”. Karabanov neither presents data on the effect of phenylpiracetam on fatigue alone, nor differentiates between disease-related fatigue and "physical" fatigue. Karabanov et al.
- Kalinskij and Nazarov describe the effect of phenylpiracetam on fatigability in the treatment of asthenic syndrome (Kalinskij and Nazarov, Zh Nevrol Psikhiatr Im SS Korsakova, 107, 61-63, 2007), and Akhapkina et al. provide additional data from a clinical study Efficacy of Phenotropil in the treatment of asthenic syndrome and chronic fatigue syndrome (Akhapkina et al., Atmosfera. Nervnye Bolezni 3, 28-31 , 2004).
- Vasilyev and Kolesnikova compared the effects of phenylpiracetam as neuroprotective therapeutic in PD to placebo treatment (Vasilyev, Y.N., and Kolesnikova, O.A., data presented at Current Issues of Experimental and Clinical Medicine, Bangkok, Pattaya, Thailand, December 20-30, 2008).
- the present invention relates to a method of improving the dopamine- replacement therapy of Parkinson's disease and/or of treating fatigue, particularly mental fatigue, associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in combination treatment with an agent for dopamine-replacement therapy of Parkinson's disease.
- Another aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
- the present invention relates to a method of treating fatigue associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
- the present invention relates to a method of treating fatigue associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
- Figure 1 shows that (R)-phenylpiracetam increases extracellular dopamine levels in rat striatum as shown by brain microdialysis.
- Figure 2 shows the concentration of (R)-phenylpiracetam in the brain, as determined by brain microdialysis, after intraperitoneal (i.p.) application.
- Affinity for DA transporter is c.a. 13 ⁇ .
- FIG. 3 shows that (R)-phenylpiracetam increases locomotor activity (horizontal activity) in rats (administration i.p. 15 min before test) ( * : p ⁇ 0.05 vs. vehicle, Kruskal- Wallis one-way ANOVA on ranks at each time interval followed by rank sum test).
- Figure 4 shows the CNS profile of (R)-phenylpiracetam in an electroencephalography (EEG) screen.
- Figure 5 shows the results from a progressive ratio test for determining the influence of (R)-phenylpiracetam on motivation in comparison to amphetamine.
- Figure 6 shows the results from a progressive ratio test for determining the influence of (R)-phenylpiracetam on motivation in comparison to methylphenidate.
- Figure 7 shows the results from a cost benefit test for determining the influence of (R)-phenylpiracetam on motivation in comparison to amphetamine.
- Figure 8 shows the results from a cost benefit test for determining the influence of (R)-phenylpiracetam on motivation in comparison to methylphenidate.
- Figure 9 shows the effect of (R)-phenylpiracetam on rotation in rats with unilateral SNc lesion (model of Parkinson's Disease).
- Figure 10 shows the effect of (R)-phenylpiracetam on rotation produced by L- DOPA in rats with unilateral SNc lesion (model of Parkinson's Disease).
- (R)- phenylpiracetam enhances L-DOPA rotations (90-150 min) but when L-DOPA effects disappear, it produces ipsilateral rotations (270-360 min). Both contra- and ipsilateral rotations indicate antiparkinsonian activity based on postsynaptic and presynaptic mechanisms, respectively.
- Figure 11 shows the effect of (R)-phenylpiracetam on dyskinesia produced by L- DOPA in rats with unilateral SNc lesion (model of Parkinson's Disease).
- (R)- phenylpiracetam did not enhance L-DOPA dyskinesia.
- Figure 12 shows the effect of (R)-phenylpiracetam on hypokinesia produced by reserpine (5 mg/kg) + alpha-methyl-p-tyrosine (250 mg/kg) (model of Parkinson's Disease).
- Figure 13 shows the effect of (R)-phenylpiracetam on hypokinesia produced by haloperidol (0.2 mg/kg) (model of Parkinson's Disease).
- Figure 14 shows that (R)-phenylpiracetam does not influence L-DOPA concentration in the brain after i.p. application as assessed using brain microdialysis.
- Figure 15 shows that L-DOPA does not influence (R)-phenylpiracetam concentration in the brain after i.p. application as assessed using brain microdialysis.
- Figure 16 shows the effect of (S)-phenylpiracetam on hypokinesia produced by haloperidol (0.2 mg/kg) (model of Parkinson's Disease) at 50 mg/kg (Fig. 14A) and at 100 mg/kg (Fig. 14B).
- the present invention relates to the use of (R)-phenylpiracetam and any of its salts, solvates and conjugates, which possesses at least an inhibitory activity on the dopamine re-uptake transporter.
- the present invention relates to a pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in combination treatment with an agent for dopamine-replacement therapy of Parkinson's disease.
- phenylpiracetam refers to the compound 2-(4- phenyl-2-oxopyrrolidin-1-yl)acetamide (C12H14N2O2; MW 218.3 g/mol). Phenylpiracetam is also known as fenotropil, phenotropyl, phenotropil, fenotropyl, or carphedon and was developed in Russia, where it is available as a prescription medicine under the name "Phenotropil ® ". As used herein, phenylpiracetam refers to the substance, as well as its pharmaceutically acceptable salts.
- Phenylpiracetam is optically active and is available as a racemate of the two enantiomers.
- the International Nonproprietary Name (INN) "Fonturacetam” has been assigned to racemic phenylpiracetam.
- An international patent application with priority date in 2006 first disclosed the separation of the two enantiomers and demonstrated that the (R)-enantiomer is predominantly responsible for the pharmacological activity (WO 2007/104780).
- (R)-phenylpiracetam showed more pronounced activity in animal models for detecting antidepressant, analgesic, muscle relaxant and psychostimulant effects.
- the patent claims (R)-phenylpiracetam for the use as an antidepressant, as a stress-protective agent, as a modulator of locomotor activity, as a muscle relaxant and as an analgesic.
- phenylpiracetam was found to activate the operant behaviour, to counteract psychodepressant effects of diazepam, to inhibit post-rotational nystagmus, and to prevent the development of retrograde amnesia. It also exhibited anticonvulsant action (Bobkov et al., Biull Eksp Biol Med. 95, 50-53, 1983) and some neuroprotective activity in experimental cerebral ischemia (Tiurenkov et al., Eksp Klin Farmakol. 70, 24-29, 2007). Thus, phenylpiracetam exhibits additional pharmacological effects, which are not yet fully identified and are differentiating phenylpiracetam from other pure dopamine re-uptake transporter inhibitors.
- phenylpiracetam is administered orally and shows a half-life of 3-5 hours.
- phenylpiracetam is a nootropic drug, which has an expressed anti-amnesic action, a direct activating effect on the integrative activity of the brain, helps consolidate memory, improves concentration and mental performance, facilitates the learning process, increases the information transfer between the hemispheres of the brain, increases the resistance of brain tissue to hypoxia and toxic effects, has anticonvulsant and anxiolytic effects, regulates the processes of activation and inhibition of central nervous system, and improves mood.
- phenylpiracetam has a positive effect on the metabolism and blood circulation in brain, stimulates the redox processes and increases energy potential through utilization of glucose, improves regional blood flow in ischemic areas of the brain. It increases noradrenaline, dopamine and serotonin content in the brain, does not affect the levels of GABA, associates neither with GABAA nor GABAB receptors, has no noticeable effect on the spontaneous bioelectric activity of the brain, does not influence respiration and the cardiovascular system. It shows no significant diuretic effect and has anorexigenic effect during treatment. According to the Russian package insert, the stimulating effect of phenylpiracetam manifests in the ability to provide a moderate effect on motor responses, to enhance physical performance.
- the moderate psychostimulant effect of the drug is combined with an anxiolytic activity, and it improves mood, has some analgesic effect and raises the threshold of pain.
- the adaptogenic effect of phenylpiracetam is manifested in increasing resistance to stress in conditions of excessive mental and physical overload, fatigue, hypokinesia and immobilization, and at low temperatures.
- nootropics was created in 1960s, with the discovery of piracetam followed by pramiracetam, oxiracetam, aniracetam, tenilsetam and others, and is nowadays often used to describe cognitive enhancers that are neuroprotective and nontoxic. Most nootropics do not have a clearly defined mechanism of action and work, and seem to exert their cognitive and/or neuroprotective effects through changes in brain blood flow, energy management etc.
- (R)-phenylpiracetam appears to have a clearly defined mechanism of action by inhibition of dopamine (DA) uptake, and behavioural effects are seen at the doses that create in the brain levels within affinity for DA uptake seen in vitro and produce an increase in the DA concentration in the brain as assessed by brain microdialysis (20 ⁇ at 50 mg/kg with an affinity constant of 6 ⁇ ; see Examples).
- DA dopamine
- (R)-phenylpiracetam acts more potently in animals, which have been treated to induce symptoms resembling Parkinson ' s disease (called here diseased or parkinsonian animals) than in normal animals. Therefore (R)- phenylpiracetam appears to be more suitable to correct deficits e.g. fatigue specific for PD than general everyday fatigue.
- (R)-phenylpiracetam apparently enhances L- DOPA effects in the medium to long term range which is not due to pharmacokinetic interactions since brain levels of either L-DOPA or (R)-phenylpiracetam are not higher in animals treated with both substances as compared to single treatment.
- compositions of the invention refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., human).
- pharmaceutically acceptable may also mean approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.
- salt is defined as a chemical containing different charged components.
- salt also includes hydrates and solvates.
- (R)-Phenylpiracetam may be used according to the invention in the form of any of pharmaceutically acceptable salts, solvates and conjugates. Any references to (R)- phenylpiracetam in this description should be understood as also referring to such salts, solvates and conjugates.
- the term "dopamine-replacement therapy” refers to the principal symptomatic treatment for PD that is based upon administration of either (i) an agent replacing, or increasing the level of, endogenous dopamine (e.g., levodopa (L-DOPA)), or (ii) of a dopamine receptor agonist (e.g., apomorphine).
- an agent replacing, or increasing the level of, endogenous dopamine e.g., levodopa (L-DOPA)
- a dopamine receptor agonist e.g., apomorphine
- LID is characterised by a mixture of choreiform, dystonic or ballistic/myoclonic movements that are observed after L-DOPA administration. It is reported that about 30% of the Parkinson patients will experience dyskinesia after 4-6 years of treatment with L-DOPA while close to 90% will suffer from this complication after 9 years. Although the cause of dyskinesia remains unknown, the main risk factor for the development of LID is young age at PD onset, the disease severity and duration as well as a high initial dose of L-DOPA treatment. Ultimately, this complication severely impairs the quality of life and well-being of the patient and therefore limits the use of this drug as most important therapeutic agent.
- LID may be related to the pulsatile and intermittent nature of L-DOPA therapy.
- dopamine is formed, stored and released by the remaining dopaminergic terminals as well as by other cellular components present in the striatum such as serotoninergic neurons. Since the striatal serotonin system remains relatively spared in most PD patients, it is believed to play an important role in determining the efficacy of L- DOPA therapy.
- treat is used herein to mean to relieve or alleviate at least one symptom of a disease in a subject.
- the term “treat” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease.
- treatment includes modifying, curative and symptomatic treatments.
- the term "subject” encompasses mammals including animals and humans.
- said agent is L-DOPA.
- the amount of said agent used in said combination treatment is reduced compared to the amount administered in the treatment cycle prior to said combination treatment.
- said agent is administered in said combination treatment at a reduced frequency compared to the frequency of administration in the treatment cycle prior to said combination treatment.
- said agent is L-DOPA.
- L-DOPA is administered once daily.
- (R)-phenylpiracetam is for use in a treatment comprising the following steps: (a) administering (R)-phenylpiracetam to a patient under dopamine- replacement therapy in combination with said agent administered for dopamine-replacement;
- step (c) increase of said agent once by 10% compared to the amount of said agent last administered according to step (b).
- said steps are performed in order to establish said combination treatment.
- said steps are performed in order to improve an established combination treatment.
- Another aspect of the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
- the term "fatigue associated with Parkinson's disease” refers to pathological fatigue that is independent of a type of fatigue, which is a normal response to physical exertion or stress (known as peripheral fatigue).
- This peripheral fatigue refers to muscle fatigue and is induced by repetitive muscle contractions (e.g. after athletics sports) (Chaudhuri and Behan, J Neurol Sci. 179(Suppl. 1 -2), 34-42, 2000; Chaudhuri and Behan, Lancet. 363, 978-88, 2004).
- Disease-orientated fatigue is not caused by muscle overuse or physical impairment outside the central nervous system.
- This central fatigue is a subjective feeling with symptoms of disease-associated mental fatigue (a subjective feeling of having impaired concentration, reduced memory, and speech difficulties) and disease-associated physical fatigue (subjective feeling of being exhausted and lacking energy).
- This subjective disease-associated fatigue can have its origin in particular embodiments by disturbance of the dopaminergic system of the CNS, particularly a lack of dopamine, and potentially also homeostatic changes, which lead to an abnormal degree of persistent tiredness, weakness or exhaustion.
- phenylpiracetam has apparently been prescribed inter alia for the treatment of stress associated with fatigue in healthy patients, as described in sections [0045] and [0049] above, phenylpiracetam has hitherto not been associated with the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
- FSS Fatigue Severity Scale
- the pharmaceutical composition is for use in the treatment of fatigue with a score on the FSS of at least 4, particular with a score of at least 4 for at least 2 weeks.
- the pharmaceutical composition is for use in the treatment of fatigue with a score on the Parkinson Fatigue Scale of at least 7.
- (R)- phenylpiracetam is present as (R)-phenylpiracetam hydrochloride.
- (R)- phenylpiracetam is for administration in a range from about 1 mg to about 250 mg/day, or in a range from about 25 mg to about 200 mg/day, or in a range from about 50 mg to about 150 mg/day.
- the term “about” or “approximately” means between 90% and 1 10% of a given value or range, i.e. "about 100” means “between 90 and 1 10". In narrower embodiments, the term “about” or “approximately” means between 95% and 105% of a given value or range, or between 98% and 102% of a given value or range, or between 99% and 101 % of a given value or range.
- (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration once a day (s.i.d.), twice a day (b.i.d.), or three times a day (t.i.d.).
- (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in an oral formulation.
- (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in combination with at least one additional pharmaceutical agent which has been shown to be effective for the treatment of Parkinson's disease.
- said at least one additional pharmaceutical agent is selected from: L-DOPA, carbidopa, other types of dopamine agonists, eltoprazine, MAO-inhibitors, COMT inhibitors, and benserazide.
- said at least one additional pharmaceutical is L-DOPA, a combination of L-DOPA and carbidopa, or a combination of L-DOPA and benserazide.
- (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in combination with at least one additional pharmaceutical agent which has been shown to be effective for the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
- said at least one additional pharmaceutical agent is selected from: rasagiline and pramipexole.
- the present invention relates to a method of treating Parkinson's disease in a subject in need thereof, comprising the step of administering a therapeutically effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
- terapéuticaally effective applied to dose or amount refers to that quantity of a compound or pharmaceutical composition sufficient to result in a desired activity upon administration to a mammal in need thereof.
- (R)-phenylpiracetam is enhancing the efficacy of a dopamine-replacement therapy.
- said dopamine-replacement therapy is the treatment with L-DOPA.
- the treatment relates to the treatment of one or more motor symptoms of PD, particularly wearing off, on-off phenomenon, and "end-of dose" dystonia.
- the treatment relates to reducing and/or delaying the onset of levodopa-induced dyskinesia (LID).
- LID levodopa-induced dyskinesia
- the present invention relates to a method of treating fatigue associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
- said fatigue is mental fatigue associated with Parkinson's disease.
- the invention relates to a method of treating fatigue with a score on the FSS of at least 4, particular with a score of at least 4 for at least 2 weeks.
- the invention relates to a method of treating fatigue with a score on the Parkinson Fatigue Scale of at least 7.
- the treatment of fatigue relates to the treatment of fatigue-associated symptoms in PD, particularly inactivity, motivational-deficit, floppiness, exhaustion, lassitude, and prostration.
- the present invention relates to a method of treating sleep-associated problems of PD patients, which have significant impact on their quality of life, particularly general tiredness, and drowsiness.
- (R)-phenylpiracetam may be administered as a single anti-fatigue agent or in combination with one or more additional pharmaceutical agents for the therapy of fatigue, particularly mental fatigue, associated with Parkinson's disease.
- said one or more additional pharmaceutical agents are selected from rasagiline and pramipexole.
- (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a range from about 1 mg to about 400 mg/day.
- (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a range from about 25 mg to about 350 mg/day.
- (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a range from about 50 mg to about 300 mg/day, particularly in a range from about 50 mg to about 150 mg/day.
- (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is administered once a day, particularly about 200 mg once a day.
- (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a multiple dose, for example twice a day, or three times a day, particularly twice a day, particularly at the dose of about 100 mg twice a day.
- compositions comprising (R)-phenylpiracetam may further comprise a carrier or excipient (all pharmaceutically acceptable).
- the compositions may be formulated e.g. for once-a-day administration, twice-a-day administration, or three times a day administration.
- carrier applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which an active compound (e.g., (R)- phenylpiracetam) is administered.
- Such pharmaceutical carriers may be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by A.R. Gennaro, 20 th Edition.
- the active ingredient e.g., (R)-phenylpiracetam
- the composition of the present invention may be used for the treatment of at least one of the mentioned disorders, wherein the treatment is adapted to or appropriately prepared for a specific administration as disclosed herein (e.g. , to once-a-day, twice-a-day, or three times a day administration).
- the package leaflet and/or the patient information contains corresponding information.
- the active ingredient e.g. , (R)-phenylpiracetam
- the composition of the present invention may be used for the manufacture of a medicament for the treatment of at least one of the mentioned disorders, wherein the medicament is adapted to or appropriately prepared for a specific administration as disclosed herein (e.g., to once-a- day, twice-a-day, or three times a day administration).
- the package leaflet and/or the patient information contains corresponding information.
- the dosage form of (R)- phenylpiracetam, or a (R)-phenylpiracetam salt may be a solid, semisolid, or liquid formulation according to the following.
- (R)-phenylpiracetam may be administered via different application routes.
- the oral and the parenteral route are the preferred route of application.
- (R)- phenylpiracetam may be formulated as a flavored liquid, a capsule or a tablet.
- (R)- phenylpiracetam may be combined with non-toxic, pharmaceutically acceptable excipients.
- the optimal therapeutically effective amount may be determined experimentally, taking into consideration the exact mode of administration, form in which the drug is administered, the indication toward which the administration is directed, the subject involved (e.g. , body weight, health, age, sex, etc.), and the preference and experience of the physician or veterinarian in charge.
- Suitable daily doses of the active ingredient of the invention in therapeutic treatment of humans are within the range from about 1 mg to about 400 mg per day (based on (R)-phenylpiracetam as free base), such as from about 25 mg to about 350 mg, or from about 50 mg to about 300 mg, particularly about 200 mg per day.
- the daily dose may be body weight-adjusted such as about 200 mg/day up to 80 kg body weight or about 240 mg/day for patients with a body weight of > 80 kg.
- (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a range from starting from about 50 mg and increasing the dose in 50 mg steps until the desired therapeutic efficacy is reached, but maximally to about 400 mg/day.
- the total amount of active ingredient per day of administration could also be higher due to reduced bioavailability, e.g. up to about 500 mg/day.
- a pharmaceutically acceptable salt a solvate, a conjugate or a derivative of (R)- phenylpiracetam, such as (R)-phenylpiracetam hydrochloride, the corresponding amount may be adjusted so that an equimolar amount is used.
- the term “conjoint administration” is used to refer to administration of (R)-phenylpiracetam, and at least one additional active agent simultaneously in different compositions, or sequentially.
- sequential administration for the sequential administration to be considered “conjoint", however, (R)- phenylpiracetam, and the at least one additional active agent must be administered separated by a time interval, which still permits the resultant beneficial effect for treating fatigue in a mammal.
- Recombinant Chinese hamster ovary (CHO) cells CHO-K1 (ATCC ® CCL- 61TM) cells stably expressing dopamine transporters are plated.
- the cells (2 x 10 5 /ml) are pre-incubated with test compound and/or vehicle in modified Tris-HEPES buffer pH 7.1 at 25°C for 20 min and 50 nM [ 3 H]-dopamine is then added for an additional 15 min incubation period.
- Non-specific signal is determined in the presence of 10 ⁇ nomifensine.
- Cells are then solubilized with 1 % SDS lysis buffer. Reduction of [ ⁇ ]- dopamine uptake by 50 percent or more (>50%) relative to vehicle controls indicates significant inhibitory activity.
- Compounds are screened at 10, 1 , 0.1 , 0.01 and 0.001 ⁇ . These same concentrations are concurrently applied to a separate group of untreated cells and evaluated for possible compound-induced cytotoxicity only if significant inhibition of uptake is
- Recombinant Madin Darby canine kidney (MDCK) cells NBL-2) (ATCC ® CCL-34TM) expressing norepinephrine transporter are plated for two days.
- Test compound and/or vehicle is pre-incubated with cells (1 x 10 5 /ml) in modified Tris- HEPES buffer pH 7.1 for 20 min at 25°C and 25 nM [ 3 H]-norepinephrine is then added for an additional 15 min incubation period.
- a lysate is obtained from solubilized cells and counted to determine [ 3 H]-norepinephrine uptake.
- EXAMPLE 2 Assessment of (R)-phenylpiracetam on extracellular dopamine levels in rat striatum using brain microdialysis - Fig. 1
- DA Dopamine
- DOPAC 3,4-Dihydroxyphenylacetic acid
- Samples (20 ⁇ ) were injected onto the high-performance liquid chromatography (HPLC) column (Reversed Phase, particle size 3 pm, C18, Thermo BDS Hypersil column, 150 mm x 2.1 mm, Thermo Scientific, USA) by a refrigerated microsampler system, consisting of a syringe pump (Gilson, model 402, France), a multi-column injector (Gilson, model 233 XL, France), and a temperature regulator (Gilson, model 832, France).
- HPLC high-performance liquid chromatography
- Chromatographic separation was performed using a mobile phase that consisted of a NaAc buffer (6.15 g/l) with methyl alcohol (2.5% v/v), Titriplex (250 mg/l), 1-octanesulfonic acid (OSA, 150 mg/l), and adjusted with glacial acetic acid to pH 4.1 (isocratic).
- the mobile phase was run through the system at a flow rate of 0.35 ml/min by an HPLC pump (Shimadzu, model LC-10AD vp, Japan). Detection
- DA and DOPAC Concentrations of DA and DOPAC were determined in the same sample, by HPLC separation and electrochemical detection. DA and DOPAC were detected electrochemically using a potentiostate (Antec Leyden, model Intro, the Netherlands) fitted with a glassy carbon electrode set at +500 mV vs. Ag/AgCI (Antec Leyden, the Netherlands). Data was analyzed by Chromatography Data System (Shimadzu, class- vp, Japan) software. Concentrations were quantified by the external standard method.
- Siliconized guide cannula (MAB 6.14.IC) (MAB, Stockhom, Sweden) were implanted unilaterally in pentobarbital anaesthetized animals aiming at the caudatus putamen (CPu; AP: +0.1 , LM: ⁇ 2.6, DV: -3.2 mm relative to bregma; -3.3 mm interaural) according to the atlas of Paxinos and Watson (loc. cit.). Rats were given at least 3 days to recover from surgery before starting microdialysis experiments.
- Microdialysis experiments were performed in the home cage of the animal.
- a microdialysis probe (MAB 6.14.4.; 4 mm exposed membrane length, polyethersulfone (PES) membrane; MAB, Sweden) was lowered through the guide cannula into the CPu (ventral position of probe tip with reference to the skull: -7.2 mm) ca. 12 hours before the sampling and left in place for the whole testing period.
- PES polyethersulfone
- the probes were perfused with aCSF at a flow rate of 2 ⁇ /min using a CMA 102 perfusion pump (CMA, Solna, Sweden).
- the composition of the aCSF was 147 mM Na + , 2.7 mM K + , 1.2 mM Ca 2+ , 0.85 mM Mg 2+ , 0.04 mM ascorbic acid.
- the animals were connected by a head block tether system (Instech, Plymouth Meeting, USA) to a dual channel liquid swivel 375/D/22QM (Instech, Plymouth Meeting, USA). Fluorinated ethylene propylene (FEP) tubing and tubing adapters (MAB, Sweden) were used.
- FEP Fluorinated ethylene propylene
- the sample collection began one hour after start of perfusion with three 20-minutes fractions (baseline). Thereafter, each rat was injected i.p. with (R)- phenylpiracetam and/or L-DOPA (25 mg/kg + benserazide, 15 mg/kg).
- the samples (40 ⁇ ) were collected automatically with a fraction collector (CMA/142; CMA, Solna, Sweden) and stored at -20°C until analysis.
- probes were inserted into a beaker with aCSF (37°C) containing 100 nM solution of (R)-phenylpiracetam or L-DOPA.
- Five samples (40 ⁇ ) were collected while only the last 2 were used for analysis of (R)- phenylpiracetam or L-DOPA concentration.
- HPLC in combination with atmospheric pressure ionization tandem mass spectrometry (API-MS/MS) was employed (HPLC (Shimadzu Prominence, Duisburg, Germany) coupled to an API 4000 Q Trap (triple quadrupole, Applied Biosystems/MDS Sciex, Darmstadt, Germany) equipped with a Turbolonspray source (ESI)).
- the analytical column was an Onyx Monolithic C18 50 mm x 2 mm (Phenomenex, Aillesburg, Germany).
- the mobile phase consisted of the eluent A water and eluent B acetonitrile both containing 0.1 % of formic acid.
- the chromatographic run consisted of a gradient over 1.5 min from 5% acetonitrile in water at start until a mobile phase composition of 50 % acetonitrile in water. A volume of 1 ml was injected in the API/MS/MS. A standard curve was used to calculate sample concentrations of studied agents in our samples.
- Figure 3 shows that (R)-phenylpiracetam increases locomotor activity (horizontal activity) in rats starting at the dose of 100 mg/kg indicating stimulatory activity.
- (R)-Phenylpiracetam was tested at four different concentrations (1 mg/kg, 12.5 mg/kg, 25 mg/kg, and 50 mg/kg) in an EEG screen as described by Dimpfel (Dimpfel, Neuropsychobiology, 58 (2008)178-86).
- the animals were allowed to acclimatize for at least 4 weeks before the study started. There was automatic control of light cycle, temperature and humidity. Light hours were 18 h in the evening - 6 h in the morning. Daily monitoring indicated that temperature and humidity remained within the target ranges of 22 ⁇ 2°C and 44 ⁇ 5% respectively. Cages, bedding, and water bottles were changed at regular intervals, i.e. every 2-3 days. Standard diet (Nohrlin H10, Altromin, D-32791 Heil, Germany) was available to the animals ad libitum. The animals had access to domestic quality mains water ad libitum.
- Rats were implanted with 4 bipolar concentric steel electrodes within a stereotactic surgical procedure during anaesthesia with ketamine. All four electrodes were placed 3 mm lateral within the left hemisphere. Dorsoventral coordinates were 4, 6, 4.2 and 8 mm and anterior coordinates were 3.7, 9.7, 5.7 and 12.2 mm for frontal cortex, striatum, hippocampus, and reticular formation, respectively (according to the atlas of Paxinos and Watson, 1982).
- a pre-constructed base plate carrying 4 bipolar stainless steel semi-micro electrodes (neurological electrodes "SNF 100" from Rhodes Medical Instruments, Inc., Summerland, CA 93067, USA) and a 5-pin-plug was fixed to the skull by dental cement interacting with 3 steel screws placed on distance into the bone.
- the distant recording spot of the electrode was the active electrode whereas the proximal spots of the four electrodes were connected to each other to give a reference.
- the base plate was carrying a plug to receive later on the transmitter (weight: 5.2 g including battery, 26 mm x 12 mm x 6 mm of size).
- EEG signals were recorded from frontal cortex, hippocampus, striatum and reticular formation of freely moving rats from inside a totally copper shielded room. Signals were wirelessly transmitted by a radio-telemetric system (Rhema Labortechnik, Hofheim, Germany, using 40 MHz as carrier frequency) and were amplified and processed as described earlier to give power spectra of 0.25 Hz resolution (Dimpfel et al. 1986; Dimpfel et al. 1988; Dimpfel et al. 1989; Dimpfel, 2003). In short, after automatic artifact rejection signals were collected in sweeps of 4 s duration and fast- fourier transformed using a Hanning window. Sampling frequency was 512 Hz.
- (R)-Phenylpiracetam produced a dose dependent attenuation of alpha2 and betal waves. The highest dosage produced a different pattern of changes in that theta power increases within the frontal cortex were observed. Motility was increased. Alpha2 waves are mainly under the control of dopamine (Dimpfel, loc. cit.). Thus, direct or indirect effects on dopaminergic neurotransmission can be expected from (R)- phenylpiracetam. Attenuation of alpha2 and betal waves has also been observed after administration drugs used for treatment of M. Parkinson (Dimpfel and Hoffmann, Neuropsychobiology, 62, 213-20, 2010). In summary (R)-phenylpiracetam shows a profile within the area of stimulatory drugs. EXAMPLE 6: Effect of (R)-phenylpiracetam in motivation tests - Figs. 5, 6, 7, 8 Test Item
- Methylphenidate purchased from Sigma (Taufkirchen, Germany) was dissolved in distilled water fresh for each test day.
- Modafinil purchased from Sequoia Research Products Limited (Pangbourne, UK) was dissolved in 1 % w/v methylcellulose (Sigma, Taufmün, Germany) in 0.9% NaCI water fresh for each test day.
- (R)- Phenylpiracetam was dissolved in distilled water fresh for each test day.
- Test 1 Progressive ratio (PR) task
- Behavioral testing was conducted in 12 operant test chambers (Med Associates, St. Albans, USA). Each chamber was equipped with a retractable lever, a food dispenser with receptacle, an overhead house light and two stimulus lights, one above the lever and the other above the food receptacle. An infrared photocell beam detected nose pokes into the food receptacle.
- the apparatus was controlled by a computer system (SmartControl®-lnterface and Med PC-software, Med Associates, St. Albans, USA). The light above the food receptacle indicated the delivery of a food pellet in the receptacle. Rats were first habituated to the operant boxes for two sessions (30 min each) on two consecutive days.
- a session lasted for 90 min or was ended when a rat failed to press the lever for consecutive 10 min.
- the value of the last completed ratio (breaking point) was recorded as well as the amount of received rewards, the perseverative lever presses, the duration of the session and the latency to respond.
- Animals of all treatment groups received respective vehicle/drug infusions 30 min pre-test on the final two sessions involving testing under a PR schedule.
- the rats had the choice between working for their preferred food (Bioserve pellets) by pressing the lever on a PR schedule as described above or obtaining lab chow being freely available in a dish (about 15 g) within the operant chamber.
- the food receptacle and the lever were positioned on the same wall of the operant chamber, the dish containing the lab chow was situated in a corner on the opposite side of the operant chamber.
- a session lasted for 90 min or ended when a rat failed to press the lever for consecutive 10 min. Thereafter the amount of lab chow ingested was calculated. Animals of all treatment groups received vehicle/drug infusions 30 min p re-test.
- (R)-Phenylpiracetam was tested in rats with unilateral SNc lesions - a preclinical model of Parkinson's disease. In some experiments it was combined with L- DOPA.In this model, ipsilateral rotations indicate a presynaptic mode of action, which is consistent with inhibition of dopamine uptake as a primary mode of action. L-DOPA produced contralateral rotations.
- (R)-Phenylpiracetam was injected i.p. in saline.
- L-DOPA 25 mg/kg
- benserazide 5 mg/kg
- Rats were injected with substance, placed in Perspex cylinders (30 cm diameter), and the rotational behaviour (360°) was scored for 120 min at 20-min intervals using TSA rotation measurement system.
- EXAMPLE 8 Effect of (R)-phenylpiracetam on L-DOPA-induced dyskinesia - Fig.
- AIMs abnormal involuntary movements
- the locomotor activity was measured in four perspex boxes (ENV-515-16, 43.2 cm x 43.2 cm x 30 cm), Med-Associates Inc. system) equipped with 4 arrays of 16 infrared photobeams placed 3 cm above the box floor. Distance travelled (DT) was used in further analysis for measuring locomotion. The recording started immediately after placing animals in the open field.
- the locomotor activity was measured in four perspex boxes (ENV-515- 16, 43.2 cm x 43.2 cm x 30 cm), Med-Associates Inc. system) equipped with 4 arrays of 16 infrared photobeams placed 3 cm above the box floor. Distance travelled (DT) was used in further analysis for measuring locomotion. The recording started immediately after placing animals in the open field.
Abstract
The present invention relates to the efficient treatment of an individual afflicted with Parkinson's disease (PD), the instant treatment comprising administering to the individual an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
Description
USE OF ( )-PHENYLPIRACETAM FOR THE TREATMENT OF
PARKINSON'S DISEASE
FIELD OF THE INVENTION
[0001] The present invention relates to the efficient treatment of an individual afflicted with Parkinson's disease (PD), the instant treatment comprising administering to the individual an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
BACKGROUND OF THE INVENTION
[0002] This invention relates to a method of treating patients afflicted with Parkinson's disease.
[0003] Parkinson's disease (PD) is one of the most common chronic neurological diseases. The classical symptoms of PD are characterized by slowness of movement (bradykinesia/akinesia), rigidity and/or tremor. These symptoms may have an idiopathic, toxic, traumatic or genetic origin (e.g. , in Parkinson's disease (PD)) or may also occur as a consequence of treatment, e.g., with dopamine receptor antagonists in schizophrenia (Parkinson syndrome). These movement disturbances can nowadays be treated rather effectively with various available PD drugs, particularly in early stages of the disease.
[0004] Currently, the principal symptomatic treatment for PD is based upon administration of dopamine-replacement therapy (e.g., levodopa (L-DOPA)) and/or therapy with dopamine receptor agonists (e.g., pramipexol). Long-term treatment with either therapy may lead to the development of dyskinesia, which is the most important motor complication that may arise in Parkinson patients. Although patients treated with dopamine receptor agonists are less prone to develop severe dyskinesia, other non- motor side effects such as somnolence, constipation, dizziness, nausea and hallucinations have been reported to be increased with this treatment option.
Concerning L-DOPA, long-term use of this treatment option leads to a reduction of its anti-parkinsonian efficacy and to the development of L-DOPA-induced dyskinesia (LID).
[0005] Additionally, in recent years it has been increasingly recognized that the current challenge of PD treatment are the so-called "non-motor" symptoms, for which satisfactory treatments are mainly lacking (Gallagher et al., Mov Disord. 25, 2493-2500, 2010). Amongst non-motor symptoms are autonomic dysfunctions (cardiovascular, urinary and gastrointestinal), sleep problems, psychosis, pain, cognitive deficits and fatigue. In clinical studies it could be demonstrated that fatigue and depression have the strongest association with a decline in the quality of PD patients' life (Beiske et al., Mov Disord. 25, 2456-60, 2010; Beiske and Svensson, Acta Neurol Scand Suppl.190, 78-81 , 2010).
[0006] Fatigue in PD is multidimensional including physical, mental and general aspects (Havlikova et al., Parkinsonism Relat Disord.14, 187-192, 2008; Havlikova et al., Eur J Neurol. 15, 475-80, 2008; Havlikova et al., J Neurol Sci. 270, 107-1 13, 2008). The physical dimensions of fatigue in PD are connected to problems regarding mobility and activity of daily living. Mental fatigue dimensions affect cognition, motivation, emotional well-being, and communication. In addition, general fatigue is related to bodily discomfort of the patients.
[0007] Fatigue associated with Parkinson's disease, as further defined below, has to be differentiated from fatigue symptoms in healthy individuals, where fatigue is a normal result of a natural reaction of body and mind to long-lasting and/or heavy burden, working, mental stress, over-stimulation or under-stimulation, jet lag, boredom, or lack of sleep. The physiological fatigue in healthy individuals is a normal response to physical exertion or stress, and its function is simply to protect the body from damage by overcharge. Such type of fatigue normally disappears spontaneously after a short recovery period. This type of fatigue isn't pathological and needs no therapeutic intervention. It is excluded from the intended medical use of the present invention.
[0008] Only the pathological disease-oriented type of fatigue is targeted by the present invention, and, unless otherwise defined, the term "fatigue" as used herein stands for the pathological form only.
[0009] A well-accepted measurement of this type of fatigue is the Fatigue Severity Scale (FSS), a self-administered unidimensional generic 9-item fatigue rating scale (Krupp et al., Arch Neurol. 46, 1 121-1 123, 1989). Each item has to be rated on a seven-grade Likert scale with a range from 1 (completely disagree) to 7 (completely agree), see Table 1. The total FSS score is mean score of the scores on respective 9 items. A total FSS score of 4 or higher present over 2 weeks prior to scoring is accepted as definition of presence of disease-oriented fatigue, especially in chronic diseases, e.g. Parkinson's disease.
Table 1 : Fatigue Severity Scale
[0010] Treatment options for fatigue in PD are rather limited. Recently studies with approved PD drugs have been published that showed besides the main effects on motor symptoms also mediocre improvement of fatigue. Those drugs are the monoamine oxidase inhibitor rasagiline (Rascol et al., Lancet Neurol. 10, 415-23, 201 1) and the dopamine agonist pramipexole (Morita et al., Intern Med. 50, 2163-2168, 201 1 ). However, a specific drug with a strong anti-fatigue effect that is well tolerated by PD patients is so far not available.
[0011] Several studies about the effect of phenotropil in Parkinson's disease have been performed in Russia.
[0012] Karabanov et al. describe an open-label study of the effects of phenylpiracetam on patients suffering from PD (Karabanov et al., Atmosfera. Nervnye Bolezni 4, 29-32, 2009). In the study report, it is mentioned that fatigue was one of the parameters being monitored in the study, and a figure is presented showing a positive effect of phenylpiracetam on the combined parameter "general activity, physical and mental fatigue, asthenization symptoms". Karabanov neither presents data on the effect of phenylpiracetam on fatigue alone, nor differentiates between disease-related fatigue and "physical" fatigue. Karabanov et al. are stressing "asthenization", a term usually denoting a condition experienced by astronauts (healthy subjects) following long-term space flights, in which following return to Earth the astronaut experiences symptoms such as fatigue, irritability, lack of appetite and sleep disorders. Interestingly, this is deriving from the original use of the compound as "cosmic drug". (Mendonca et al., Mov. Disord. 22, 2070-2076, 2007).
[0013] Similarly, Kalinskij and Nazarov, describe the effect of phenylpiracetam on fatigability in the treatment of asthenic syndrome (Kalinskij and Nazarov, Zh Nevrol Psikhiatr Im SS Korsakova, 107, 61-63, 2007), and Akhapkina et al. provide additional data from a clinical study Efficacy of Phenotropil in the treatment of asthenic syndrome and chronic fatigue syndrome (Akhapkina et al., Atmosfera. Nervnye Bolezni 3, 28-31 , 2004).
[0014] Vasiliev and Grigorjeva report the results of another study of phenylpiracetam in PD patients (Vasiliev, Y.N., and Grigorjeva, N.A., Siberian Medical Magazine, 2009). They report that the use of phenylpiracetam at dosages of 100 or 200 mg/day resulted in a decrease in neurological deficiencies, hypokinesia, and the level of depression, that its use prevented deterioration of sleep quality; and that phenylpiracetam in a dose of 100 mg/day quickly reduced the level of reactive anxiety; while it didn't affect mental abilities. The effect on the vegetative status was described as unambiguous.
[0015] Kolesnikova and Vasilyev analyzed the effect of phenylpiracetam on depression in PD, and concluded that phenylpiracetam contributed to a reduction of the level of depression (Kolesnikova, O.A, and Vasilyev, Y.N., Progress of Modern Natural Sciences 2008, 45-46).
[0016] Vasilyev and Kolesnikova compared the effects of phenylpiracetam as neuroprotective therapeutic in PD to placebo treatment (Vasilyev, Y.N., and Kolesnikova, O.A., data presented at Current Issues of Experimental and Clinical Medicine, Bangkok, Pattaya, Thailand, December 20-30, 2008).
[0017] Thus, despite the fact that many attempts have been made to (i) improve the current L-DOPA-based treatment scheme, and (ii) develop agents for the treatment of fatigue associated with Parkinson's disease, so far these attempts have had no clinically meaningful success in patients.
[0018] Thus, there is still a large unmet need to identify medicaments for improving the L-DOPA-based treatment of PD, and for the treatment of fatigue associated with Parkinson's disease.
[0019] The solution provided by the present invention to solve this problem, i.e. the use of a particular compound, has so far not been achieved or suggested by the prior art.
SUMMARY OF THE INVENTION
[0020] The present invention relates to a method of improving the dopamine- replacement therapy of Parkinson's disease and/or of treating fatigue, particularly mental fatigue, associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
[0021] Thus, in a first aspect the present invention relates to a pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt
thereof for use in combination treatment with an agent for dopamine-replacement therapy of Parkinson's disease.
[0022] Another aspect of the invention relates to a pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
[0023] In another aspect the present invention relates to a method of treating fatigue associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
[0024] In another aspect the present invention relates to a method of treating fatigue associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 shows that (R)-phenylpiracetam increases extracellular dopamine levels in rat striatum as shown by brain microdialysis.
[0026] Figure 2 shows the concentration of (R)-phenylpiracetam in the brain, as determined by brain microdialysis, after intraperitoneal (i.p.) application. Affinity for DA transporter is c.a. 13 μΜ.
[0027] Figure 3 shows that (R)-phenylpiracetam increases locomotor activity (horizontal activity) in rats (administration i.p. 15 min before test) (*: p< 0.05 vs. vehicle, Kruskal- Wallis one-way ANOVA on ranks at each time interval followed by rank sum test).
[0028] Figure 4 shows the CNS profile of (R)-phenylpiracetam in an electroencephalography (EEG) screen.
[0029] Figure 5 shows the results from a progressive ratio test for determining the influence of (R)-phenylpiracetam on motivation in comparison to amphetamine.
[0030] Figure 6 shows the results from a progressive ratio test for determining the influence of (R)-phenylpiracetam on motivation in comparison to methylphenidate.
[0031] Figure 7 shows the results from a cost benefit test for determining the influence of (R)-phenylpiracetam on motivation in comparison to amphetamine.
[0032] Figure 8 shows the results from a cost benefit test for determining the influence of (R)-phenylpiracetam on motivation in comparison to methylphenidate.
[0033] Figure 9 shows the effect of (R)-phenylpiracetam on rotation in rats with unilateral SNc lesion (model of Parkinson's Disease).
[0034] Figure 10 shows the effect of (R)-phenylpiracetam on rotation produced by L- DOPA in rats with unilateral SNc lesion (model of Parkinson's Disease). (R)- phenylpiracetam enhances L-DOPA rotations (90-150 min) but when L-DOPA effects disappear, it produces ipsilateral rotations (270-360 min). Both contra- and ipsilateral rotations indicate antiparkinsonian activity based on postsynaptic and presynaptic mechanisms, respectively.
[0035] Figure 11 shows the effect of (R)-phenylpiracetam on dyskinesia produced by L- DOPA in rats with unilateral SNc lesion (model of Parkinson's Disease). (R)- phenylpiracetam did not enhance L-DOPA dyskinesia.
[0036] Figure 12 shows the effect of (R)-phenylpiracetam on hypokinesia produced by reserpine (5 mg/kg) + alpha-methyl-p-tyrosine (250 mg/kg) (model of Parkinson's Disease).
[0037] Figure 13 shows the effect of (R)-phenylpiracetam on hypokinesia produced by haloperidol (0.2 mg/kg) (model of Parkinson's Disease).
[0038] Figure 14 shows that (R)-phenylpiracetam does not influence L-DOPA concentration in the brain after i.p. application as assessed using brain microdialysis.
[0039] Figure 15 shows that L-DOPA does not influence (R)-phenylpiracetam concentration in the brain after i.p. application as assessed using brain microdialysis.
[0040] Figure 16 shows the effect of (S)-phenylpiracetam on hypokinesia produced by haloperidol (0.2 mg/kg) (model of Parkinson's Disease) at 50 mg/kg (Fig. 14A) and at 100 mg/kg (Fig. 14B).
DETAILED DESCRIPTION OF THE INVENTION
[0041] The peculiarity of this invention compared to former treatment approaches for treating Parkinson's disease and/or fatigue associated with Parkinson's disease is the so far unknown therapeutic efficacy of (R)-phenylpiracetam, which is presumably based at least in part on the newly identified activity of (R)-phenylpiracetam as the dopamine re-uptake inhibitor.
[0042] Thus, the present invention relates to the use of (R)-phenylpiracetam and any of its salts, solvates and conjugates, which possesses at least an inhibitory activity on the dopamine re-uptake transporter.
[0043] Thus, in a first aspect the present invention relates to a pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in combination treatment with an agent for dopamine-replacement therapy of Parkinson's disease.
[0044] The term "phenylpiracetam" is known in the art and refers to the compound 2-(4- phenyl-2-oxopyrrolidin-1-yl)acetamide (C12H14N2O2; MW 218.3 g/mol). Phenylpiracetam is also known as fenotropil, phenotropyl, phenotropil, fenotropyl, or carphedon and was developed in Russia, where it is available as a prescription medicine under the name "Phenotropil®". As used herein, phenylpiracetam refers to the substance, as well as its pharmaceutically acceptable salts.
[0045] Phenylpiracetam is optically active and is available as a racemate of the two enantiomers. The International Nonproprietary Name (INN) "Fonturacetam" has been assigned to racemic phenylpiracetam. An international patent application with priority date in 2006 first disclosed the separation of the two enantiomers and demonstrated that the (R)-enantiomer is predominantly responsible for the pharmacological activity (WO 2007/104780). (R)-phenylpiracetam showed more pronounced activity in animal models for detecting antidepressant, analgesic, muscle relaxant and psychostimulant effects. The patent claims (R)-phenylpiracetam for the use as an antidepressant, as a stress-protective agent, as a modulator of locomotor activity, as a muscle relaxant and as an analgesic.
[0046] More detailed pharmacological data of (R)-phenylpiracetam have been published recently by the same authors (Zvejniece et al., Basic Clin Pharmacol Toxicol. 109, 407- 412, 2011 ). In the open-field test a significant increase in locomotor activity was found, which was just slightly stronger with the (R)-phenylpiracetam than with (S)- phenylpiracetam. Also in the forced swim test, used as a model for depression, (R)- phenylpiracetam was also only slightly more potent than (S)-phenylpiracetam. However, in the passive avoidance test (R)-phenylpiracetam enhanced memory function significantly better compared to (S)-phenylpiracetam. The authors conclude that these results may be important for the clinical use of optically pure isomers of phenylpiracetam.
[0047] Prior to the surprising finding of the present inventors that (R)-phenylpiracetam acts as a dopamine re-uptake transporter inhibitor, the precise pharmacological mechanism of action of (R)-phenylpiracetam had not been elucidated. In pharmacological studies phenylpiracetam was found to activate the operant behaviour, to counteract psychodepressant effects of diazepam, to inhibit post-rotational nystagmus, and to prevent the development of retrograde amnesia. It also exhibited anticonvulsant action (Bobkov et al., Biull Eksp Biol Med. 95, 50-53, 1983) and some neuroprotective activity in experimental cerebral ischemia (Tiurenkov et al., Eksp Klin Farmakol. 70, 24-29, 2007). Thus, phenylpiracetam exhibits additional pharmacological effects, which are not yet fully identified and are differentiating phenylpiracetam from other pure dopamine re-uptake transporter inhibitors.
[0048] In humans phenylpiracetam is administered orally and shows a half-life of 3-5 hours. There are only a small number of low-scale exploratory clinical trials predominantly published in Russian journals. They have shown possible links between intake of phenylpiracetam and improvement in a number of conditions and diseases including asthenic syndrome and autonomic disturbances in brain trauma (Kalinskij and Nazarov, Zh Nevrol Psikhiatr Im S S Korsakova.107, 61-63, 2007), brain organic lesions (Savchenko et al. Zh Nevrol Psikhiatr Im S S Korsakova.105, 22-26, 2005), epilepsy (Bel'skaia et al. Zh Nevrol Psikhiatr Im S S Korsakova.107, 40-43, 2007, Lybzikova et al., Zh Nevrol Psikhiatr Im S S Korsakova.108, 69-70, 2008), stomatological problems (Novikova et al. Stomatologiia (Mosk).87, 41-45, 2008), and vascular encephalopathy (Gustov et al. Zh Nevrol Psikhiatr Im S S Korsakova.106, 52-53, 2006). Effects of phenylpiracetam on immunological consequences of stroke have also been described (Gerasimova et al., Zh Nevrol Psikhiatr Im S S Korsakova.105, 63-64, 2005).
[0049] According to the package insert of the drug as approved in Russia, phenylpiracetam is a nootropic drug, which has an expressed anti-amnesic action, a direct activating effect on the integrative activity of the brain, helps consolidate memory, improves concentration and mental performance, facilitates the learning process, increases the information transfer between the hemispheres of the brain, increases the resistance of brain tissue to hypoxia and toxic effects, has anticonvulsant and anxiolytic
effects, regulates the processes of activation and inhibition of central nervous system, and improves mood. It is furthermore stated that phenylpiracetam has a positive effect on the metabolism and blood circulation in brain, stimulates the redox processes and increases energy potential through utilization of glucose, improves regional blood flow in ischemic areas of the brain. It increases noradrenaline, dopamine and serotonin content in the brain, does not affect the levels of GABA, associates neither with GABAA nor GABAB receptors, has no noticeable effect on the spontaneous bioelectric activity of the brain, does not influence respiration and the cardiovascular system. It shows no significant diuretic effect and has anorexigenic effect during treatment. According to the Russian package insert, the stimulating effect of phenylpiracetam manifests in the ability to provide a moderate effect on motor responses, to enhance physical performance. The moderate psychostimulant effect of the drug is combined with an anxiolytic activity, and it improves mood, has some analgesic effect and raises the threshold of pain. The adaptogenic effect of phenylpiracetam is manifested in increasing resistance to stress in conditions of excessive mental and physical overload, fatigue, hypokinesia and immobilization, and at low temperatures.
[0050] As shown above in sections [0012] to [0016], phenylpiracetam has been tested in some clinical studies in patients suffering from Parkinson's disease. While the publications listed above report some positive effects on certain symptoms associated with Parkinson's disease, no clear picture about potentially beneficial applications of phenylpiracetam emerged from these studies.
[0051] While (R)-phenylpiracetam was synthesized and described in the literature as nootropic compound, the present applicants have surprisingly found that (R)- phenylpiracetam has features not fitting into class of nootropics.
[0052] The term nootropics was created in 1960s, with the discovery of piracetam followed by pramiracetam, oxiracetam, aniracetam, tenilsetam and others, and is nowadays often used to describe cognitive enhancers that are neuroprotective and nontoxic. Most nootropics do not have a clearly defined mechanism of action and work, and seem to exert their cognitive and/or neuroprotective effects through changes in brain blood flow, energy management etc.
[0053] In contrast to nootropics, (R)-phenylpiracetam appears to have a clearly defined mechanism of action by inhibition of dopamine (DA) uptake, and behavioural effects are seen at the doses that create in the brain levels within affinity for DA uptake seen in vitro and produce an increase in the DA concentration in the brain as assessed by brain microdialysis (20 μΜ at 50 mg/kg with an affinity constant of 6 μΜ; see Examples).
[0054] Furthermore, in the EEG pattern there is a clear difference between nootropics and (R)-phenylpiracetam. For nootropics, a decrease of power for nearly all waves can be shown in the reticular formation, while there is no change of theta, delta, alphal and beta2 waves for (R)-phenylpiracetam (see Examples).
[0055] Additionally, (R)-phenylpiracetam acts more potently in animals, which have been treated to induce symptoms resembling Parkinson's disease (called here diseased or parkinsonian animals) than in normal animals. Therefore (R)- phenylpiracetam appears to be more suitable to correct deficits e.g. fatigue specific for PD than general everyday fatigue.
[0056] Finally, it could be shown that (R)-phenylpiracetam apparently enhances L- DOPA effects in the medium to long term range which is not due to pharmacokinetic interactions since brain levels of either L-DOPA or (R)-phenylpiracetam are not higher in animals treated with both substances as compared to single treatment.
[0057] The phrase "pharmaceutically acceptable", as used in connection with compositions of the invention, refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., human). The term "pharmaceutically acceptable" may also mean approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.
[0058] The term "salt" is defined as a chemical containing different charged components. The term salt also includes hydrates and solvates.
[0059] (R)-Phenylpiracetam may be used according to the invention in the form of any of pharmaceutically acceptable salts, solvates and conjugates. Any references to (R)- phenylpiracetam in this description should be understood as also referring to such salts, solvates and conjugates.
[0060] In the context of the present invention, the term "dopamine-replacement therapy" refers to the principal symptomatic treatment for PD that is based upon administration of either (i) an agent replacing, or increasing the level of, endogenous dopamine (e.g., levodopa (L-DOPA)), or (ii) of a dopamine receptor agonist (e.g., apomorphine). Long- term treatment with either therapy may lead to the development of dyskinesia, which is the most important motor complication that may arise in Parkinson patients. Although patients treated with dopamine receptor agonists are less prone to develop severe dyskinesia, other non-motor side effects such as somnolence, constipation, dizziness, nausea and hallucination have been reported to be increased with this treatment option. Concerning L-DOPA, long-term use of this treatment option leads to a reduction of its anti-parkinsonian efficacy and to the development of L-DOPA-induced dyskinesia (LID).
[0061] LID is characterised by a mixture of choreiform, dystonic or ballistic/myoclonic movements that are observed after L-DOPA administration. It is reported that about 30% of the Parkinson patients will experience dyskinesia after 4-6 years of treatment with L-DOPA while close to 90% will suffer from this complication after 9 years. Although the cause of dyskinesia remains unknown, the main risk factor for the development of LID is young age at PD onset, the disease severity and duration as well as a high initial dose of L-DOPA treatment. Ultimately, this complication severely impairs the quality of life and well-being of the patient and therefore limits the use of this drug as most important therapeutic agent.
[0062] According to the literature, LID may be related to the pulsatile and intermittent nature of L-DOPA therapy. Upon systemic administration of L-DOPA to Parkinson patients, dopamine is formed, stored and released by the remaining dopaminergic terminals as well as by other cellular components present in the striatum such as serotoninergic neurons. Since the striatal serotonin system remains relatively spared in
most PD patients, it is believed to play an important role in determining the efficacy of L- DOPA therapy.
[0063] The term "treat" is used herein to mean to relieve or alleviate at least one symptom of a disease in a subject. Within the meaning of the present invention, the term "treat" also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease. Thus, "treatment" as used herein includes modifying, curative and symptomatic treatments.
[0064] As used herein, the term "subject" encompasses mammals including animals and humans.
[0065] In particular embodiments, said agent is L-DOPA.
[0066] In particular embodiments, the amount of said agent used in said combination treatment is reduced compared to the amount administered in the treatment cycle prior to said combination treatment.
[0067] In particular embodiments, said agent is administered in said combination treatment at a reduced frequency compared to the frequency of administration in the treatment cycle prior to said combination treatment.
[0068] In particular embodiments, said agent is L-DOPA. In particular such embodiments, L-DOPA is administered once daily.
[0069] In particular embodiments, (R)-phenylpiracetam is for use in a treatment comprising the following steps:
(a) administering (R)-phenylpiracetam to a patient under dopamine- replacement therapy in combination with said agent administered for dopamine-replacement;
(b) reduction of said agent in daily increments of 10% until signs of Parkinson's symptoms re-emerge; and
(c) increase of said agent once by 10% compared to the amount of said agent last administered according to step (b).; and
(d) continuation of the combination treatment using (R)-phenylpiracetam and the amount of said agent used in accordance with step (c).
[0070] In particular embodiments, said steps are performed in order to establish said combination treatment.
[0071 ] In particular embodiments, said steps are performed in order to improve an established combination treatment.
[0072] Another aspect of the invention relates to a pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
[0073] In the context of the present invention, the term "fatigue associated with Parkinson's disease" refers to pathological fatigue that is independent of a type of fatigue, which is a normal response to physical exertion or stress (known as peripheral fatigue). This peripheral fatigue refers to muscle fatigue and is induced by repetitive muscle contractions (e.g. after athletics sports) (Chaudhuri and Behan, J Neurol Sci. 179(Suppl. 1 -2), 34-42, 2000; Chaudhuri and Behan, Lancet. 363, 978-88, 2004). Disease-orientated fatigue is not caused by muscle overuse or physical impairment outside the central nervous system. This central fatigue is a subjective feeling with
symptoms of disease-associated mental fatigue (a subjective feeling of having impaired concentration, reduced memory, and speech difficulties) and disease-associated physical fatigue (subjective feeling of being exhausted and lacking energy). This subjective disease-associated fatigue can have its origin in particular embodiments by disturbance of the dopaminergic system of the CNS, particularly a lack of dopamine, and potentially also homeostatic changes, which lead to an abnormal degree of persistent tiredness, weakness or exhaustion.
[0074] While phenylpiracetam has apparently been prescribed inter alia for the treatment of stress associated with fatigue in healthy patients, as described in sections [0045] and [0049] above, phenylpiracetam has hitherto not been associated with the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
[0075] As reported above in Section [0012], Karabanov et al. reported certain observations related to the effect of phenylpiracetam on fatigue, but did neither differentiate between disease-related fatigue and "physiological" fatigue, and instead focussed on "asthenization". In contrast, the so-called "Parkinson Fatigue" is an outstanding embodiment of disease-associated fatigue seen exclusively in PD patients. Using common rating scales for fatigue causes problems in PD patients, as the critical assessment of Friedman JH et al (Mov. Disorders 25, 805-822, 2010) revealed. The "Parkinson Fatigue Scale" developed by Brown RG et al. (Parkinsonism Related DisordersH , 49-55, 2005) excludes emotional and cognitive features that may occur as part of the fatigue experience but which may also occur independently in Parkinsonism. The 16 specific items of this scale are reported by the affected patients themselves and allow a clear separation of the Parkinson-specific type of fatigue from other types of fatigue, wherein the cut-off point is at 7 (binary calculation).
[0076] A well-accepted measurement of this type of fatigue is the Fatigue Severity Scale (FSS), which has been described above.
[0077] In particular embodiments, the pharmaceutical composition is for use in the treatment of fatigue with a score on the FSS of at least 4, particular with a score of at least 4 for at least 2 weeks.
[0078] In particular embodiments, the pharmaceutical composition is for use in the treatment of fatigue with a score on the Parkinson Fatigue Scale of at least 7.
[0079] In particular embodiments of the methods of the present invention, (R)- phenylpiracetam is present as (R)-phenylpiracetam hydrochloride.
[0080] In particular embodiments of the methods of the present invention, (R)- phenylpiracetam is for administration in a range from about 1 mg to about 250 mg/day, or in a range from about 25 mg to about 200 mg/day, or in a range from about 50 mg to about 150 mg/day.
[0081 ] In the context of the present invention, the term "about" or "approximately" means between 90% and 1 10% of a given value or range, i.e. "about 100" means "between 90 and 1 10". In narrower embodiments, the term "about" or "approximately" means between 95% and 105% of a given value or range, or between 98% and 102% of a given value or range, or between 99% and 101 % of a given value or range.
[0082] In particular embodiments of the methods of the present invention, (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration once a day (s.i.d.), twice a day (b.i.d.), or three times a day (t.i.d.).
[0083] In particular embodiments of the methods of the present invention, (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in an oral formulation.
[0084] In particular embodiments of the methods of the present invention, (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in combination with at least one additional pharmaceutical agent which has been shown to be effective for the treatment of Parkinson's disease.
[0085] In particular embodiments, said at least one additional pharmaceutical agent is selected from: L-DOPA, carbidopa, other types of dopamine agonists, eltoprazine, MAO-inhibitors, COMT inhibitors, and benserazide. In particular embodiments, said at least one additional pharmaceutical is L-DOPA, a combination of L-DOPA and carbidopa, or a combination of L-DOPA and benserazide.
[0086] In particular embodiments of the methods of the present invention, (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in combination with at least one additional pharmaceutical agent which has been shown to be effective for the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
[0087] In particular embodiments, said at least one additional pharmaceutical agent is selected from: rasagiline and pramipexole.
[0088] In another aspect the present invention relates to a method of treating Parkinson's disease in a subject in need thereof, comprising the step of administering a therapeutically effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
[0089] The term "therapeutically effective" applied to dose or amount refers to that quantity of a compound or pharmaceutical composition sufficient to result in a desired activity upon administration to a mammal in need thereof.
[0090] In particular embodiments, (R)-phenylpiracetam is enhancing the efficacy of a dopamine-replacement therapy.
[0091] In a particular embodiment, said dopamine-replacement therapy is the treatment with L-DOPA.
[0092] In certain embodiments, the treatment relates to the treatment of one or more motor symptoms of PD, particularly wearing off, on-off phenomenon, and "end-of dose" dystonia.
[0093] In certain embodiments, the treatment relates to reducing and/or delaying the onset of levodopa-induced dyskinesia (LID).
[0094] In another aspect the present invention relates to a method of treating fatigue associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
[0095] In particular embodiments, said fatigue is mental fatigue associated with Parkinson's disease.
[0096] In particular embodiments, the invention relates to a method of treating fatigue with a score on the FSS of at least 4, particular with a score of at least 4 for at least 2 weeks.
[0097] In particular embodiments, the invention relates to a method of treating fatigue with a score on the Parkinson Fatigue Scale of at least 7.
[0098] In certain embodiments, the treatment of fatigue relates to the treatment of fatigue-associated symptoms in PD, particularly inactivity, motivational-deficit, floppiness, exhaustion, lassitude, and prostration.
[0099] In certain embodiments, the present invention relates to a method of treating sleep-associated problems of PD patients, which have significant impact on their quality of life, particularly general tiredness, and drowsiness.
[00100] (R)-phenylpiracetam may be administered as a single anti-fatigue agent or in combination with one or more additional pharmaceutical agents for the therapy of fatigue, particularly mental fatigue, associated with Parkinson's disease.
[00101 ] In particular such embodiments, said one or more additional pharmaceutical agents are selected from rasagiline and pramipexole.
[00102] In certain embodiments of the method of the present invention, (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a range from about 1 mg to about 400 mg/day.
[00103] In a further embodiment of the method of the present invention, (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a range from about 25 mg to about 350 mg/day.
[00104] In a still further embodiment, (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a range from about 50 mg to about 300 mg/day, particularly in a range from about 50 mg to about 150 mg/day.
[00105] In yet another embodiment of the method of the present invention, (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is administered once a day, particularly about 200 mg once a day.
[00106] In yet another embodiment of the method of the present invention, (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a multiple dose, for example twice a day, or three times a day, particularly twice a day, particularly at the dose of about 100 mg twice a day.
[00107] In conjunction with the aspects of the present invention, the pharmaceutical compositions comprising (R)-phenylpiracetam may further comprise a carrier or excipient (all pharmaceutically acceptable). The compositions may be formulated e.g. for once-a-day administration, twice-a-day administration, or three times a day administration.
[00108] The term "carrier" applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which an active compound (e.g., (R)-
phenylpiracetam) is administered. Such pharmaceutical carriers may be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by A.R. Gennaro, 20th Edition.
[00109] The active ingredient (e.g., (R)-phenylpiracetam) or the composition of the present invention may be used for the treatment of at least one of the mentioned disorders, wherein the treatment is adapted to or appropriately prepared for a specific administration as disclosed herein (e.g. , to once-a-day, twice-a-day, or three times a day administration). For this purpose the package leaflet and/or the patient information contains corresponding information.
[001 10] The active ingredient (e.g. , (R)-phenylpiracetam) or the composition of the present invention may be used for the manufacture of a medicament for the treatment of at least one of the mentioned disorders, wherein the medicament is adapted to or appropriately prepared for a specific administration as disclosed herein (e.g., to once-a- day, twice-a-day, or three times a day administration). For this purpose the package leaflet and/or the patient information contains corresponding information.
[001 1 1 ] According to the present invention, the dosage form of (R)- phenylpiracetam, or a (R)-phenylpiracetam salt, may be a solid, semisolid, or liquid formulation according to the following.
[001 12] (R)-phenylpiracetam may be administered via different application routes. The oral and the parenteral route are the preferred route of application. (R)- phenylpiracetam may be formulated as a flavored liquid, a capsule or a tablet.
[001 13] For oral administration in the form of a tablet or capsule, (R)- phenylpiracetam may be combined with non-toxic, pharmaceutically acceptable excipients.
[001 14] The optimal therapeutically effective amount may be determined experimentally, taking into consideration the exact mode of administration, form in which the drug is administered, the indication toward which the administration is directed, the subject involved (e.g. , body weight, health, age, sex, etc.), and the preference and experience of the physician or veterinarian in charge.
[001 15] Suitable daily doses of the active ingredient of the invention in therapeutic treatment of humans are within the range from about 1 mg to about 400 mg per day (based on (R)-phenylpiracetam as free base), such as from about 25 mg to about 350 mg, or from about 50 mg to about 300 mg, particularly about 200 mg per day. In an alternative setting, the daily dose may be body weight-adjusted such as about 200 mg/day up to 80 kg body weight or about 240 mg/day for patients with a body weight of > 80 kg. In a further alternative setting, (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is administered in a range from starting from about 50 mg and increasing the dose in 50 mg steps until the desired therapeutic efficacy is reached, but maximally to about 400 mg/day. Furthermore, in modified release formulations the total amount of active ingredient per day of administration could also be higher due to reduced bioavailability, e.g. up to about 500 mg/day. For use of a pharmaceutically acceptable salt, a solvate, a conjugate or a derivative of (R)- phenylpiracetam, such as (R)-phenylpiracetam hydrochloride, the corresponding amount may be adjusted so that an equimolar amount is used.
[001 16] In certain embodiment, wherein (R)-phenylpiracetam is administered, or where a composition comprising (R)-phenylpiracetam is for administration, with a second agent, the administration may be conjoint or separate.
[001 17] Within the meaning of the present invention, the term "conjoint administration" is used to refer to administration of (R)-phenylpiracetam, and at least one additional active agent simultaneously in different compositions, or sequentially. For the sequential administration to be considered "conjoint", however, (R)- phenylpiracetam, and the at least one additional active agent must be administered separated by a time interval, which still permits the resultant beneficial effect for treating fatigue in a mammal.
EXAMPLES
[001 18] The following example illustrates the invention without limiting its scope.
EXAMPLE 1 : Determination of (R)-phenylpiracetam targets
[001 19] Using functional monoamine transporter assays, we determined the potential drug targets for (R)-phenylpiracetam.
[00120] Recombinant Chinese hamster ovary (CHO) cells CHO-K1 (ATCC® CCL- 61™) cells stably expressing dopamine transporters are plated. The cells (2 x 105/ml) are pre-incubated with test compound and/or vehicle in modified Tris-HEPES buffer pH 7.1 at 25°C for 20 min and 50 nM [3H]-dopamine is then added for an additional 15 min incubation period. Non-specific signal is determined in the presence of 10 μΜ nomifensine. Cells are then solubilized with 1 % SDS lysis buffer. Reduction of [Ή]- dopamine uptake by 50 percent or more (>50%) relative to vehicle controls indicates significant inhibitory activity. Compounds are screened at 10, 1 , 0.1 , 0.01 and 0.001 μΜ. These same concentrations are concurrently applied to a separate group of untreated cells and evaluated for possible compound-induced cytotoxicity only if significant inhibition of uptake is observed.
[00121] Recombinant Madin Darby canine kidney (MDCK) cells (NBL-2) (ATCC® CCL-34™) expressing norepinephrine transporter are plated for two days. Test compound and/or vehicle is pre-incubated with cells (1 x 105/ml) in modified Tris- HEPES buffer pH 7.1 for 20 min at 25°C and 25 nM [3H]-norepinephrine is then added for an additional 15 min incubation period. A lysate is obtained from solubilized cells and counted to determine [3H]-norepinephrine uptake. Reduction of [3H]-norepinephrine uptake by 50 percent or more (>50%) relative to 10 μΜ desipramine indicates significant inhibitory activity. Compounds are screened at 10, 1 , 0.1 , 0.01 and 0.001 μΜ. These same concentrations are concurrently applied to a separate group of untreated cells and evaluated for possible compound-induced cytotoxicity only if significant inhibition of uptake is observed.
[00122] These pharmacological experiments showed an affinity of (R)- phenylpiracetam for the neuronal dopamine re-uptake transporter of 13 μΜ in functional assays.
[00123] In microdialysis experiments, we could show that at a behaviorally active dose of 100 mg/kg a free concentration 50 μΜ is reached in extracellular fluid in the brain, and at 50 mg/kg a free concentration of 20 μΜ.
[00124] These concentrations are sufficiently high to postulate that the dopamine re-uptake transporter is a relevant target in the brain.
EXAMPLE 2: Assessment of (R)-phenylpiracetam on extracellular dopamine levels in rat striatum using brain microdialysis - Fig. 1
Test Item
[00 25] (R)-Phenylpiracetam was dissolved in saline and injected intraperitoneally (i.p).
Animals
[00126] Adult male Sprague-Dawley rats (n = 5, -300 g; Harlan, The Netherlands) were used for the experiments. After surgery animals were housed individually (cages 30 cm x 30 cm x 40 cm) with food and water was ad libitum available at standard conditions. The post-surgery interval for recovery was minimally 48 h.
Surgery
[00127] Rats were anesthetized using isoflurane (2%, 800 ml/min O2). and placed in a stereotaxic frame (Kopf instruments, USA), l-shaped probes (Hospal AN 69 membrane, 3 mm exposed surface; Brainlink, the Netherlands) were inserted into striatum. Coordinates for the tips of the probes were: posterior (AP) = + 0.9 mm to
bregma, lateral (L) = +3.0 mm to midline and ventral (V) = -6.5 mm to dura (Paxinos and Watson, 982).
Microdialysis experiments
[00128] Experiments were performed 24-48 hours after surgery. On the day of the experiment, the probes were connected with flexible polyether ether ketone (PEEK) tubing to a microperfusion pump (Syringe pump UV 8301501 , Univentor, Malta) and perfused with artificial cerebro-spinal fluid (aCSF), containing 147 mM NaCI, 3.0 mM KCI, 1.2 mM CaCI2, and 1.2 mM MgCI2> at a flow rate of 1.5 μΙ/min. Microdialysis samples were collected for 20 minute periods up to 120 min using automated fraction collector (Univentor 820 Microsampler, Antec, Netherlands), and stored at -80°C pending analysis. After the experiment, the rats were sacrificed and the brains were removed. The position of each probe was histologically verified according to Paxinos and Watson (1982) by making coronal sections of the brain.
Determination of Dopamine (DA) and 3,4-Dihydroxyphenylacetic acid (DOPAC) Separation of DA and DOPAC
[00129] Samples (20 μΙ) were injected onto the high-performance liquid chromatography (HPLC) column (Reversed Phase, particle size 3 pm, C18, Thermo BDS Hypersil column, 150 mm x 2.1 mm, Thermo Scientific, USA) by a refrigerated microsampler system, consisting of a syringe pump (Gilson, model 402, France), a multi-column injector (Gilson, model 233 XL, France), and a temperature regulator (Gilson, model 832, France). Chromatographic separation was performed using a mobile phase that consisted of a NaAc buffer (6.15 g/l) with methyl alcohol (2.5% v/v), Titriplex (250 mg/l), 1-octanesulfonic acid (OSA, 150 mg/l), and adjusted with glacial acetic acid to pH 4.1 (isocratic). The mobile phase was run through the system at a flow rate of 0.35 ml/min by an HPLC pump (Shimadzu, model LC-10AD vp, Japan).
Detection
[00130] Concentrations of DA and DOPAC were determined in the same sample, by HPLC separation and electrochemical detection. DA and DOPAC were detected electrochemically using a potentiostate (Antec Leyden, model Intro, the Netherlands) fitted with a glassy carbon electrode set at +500 mV vs. Ag/AgCI (Antec Leyden, the Netherlands). Data was analyzed by Chromatography Data System (Shimadzu, class- vp, Japan) software. Concentrations were quantified by the external standard method.
Statistical Analysis
[00131] After transmitter levels were stabilized, four consecutive pre-treatment microdialysis samples with less than 50% variation were taken as baseline and their mean was set at 100%. After compound 3-2008 (100 mg/kg) was administered 13 more fractions were taken. Transmitter concentration in each fraction was expressed as % ± SEM (standard error mean) of baseline.
Results
[00132] The results show that (R)-phenylpiracetam increases concentration of dopamine in the striatum.
EXAMPLE 3; Assessment of the concentration of (R)-phenylpiracetam in the
brain using brain microdialysis - Figs. 2, 14, 15
Subjects
[00133] Naive adult male Sprague-Dawley rats (240-360 g, Janvier, France) were used for the study kept under standard conditions. All experiments were conducted during the light period of the day-night cycle.
Surgery
[00134] Siliconized guide cannula (MAB 6.14.IC) (MAB, Stockhom, Sweden) were implanted unilaterally in pentobarbital anaesthetized animals aiming at the caudatus
putamen (CPu; AP: +0.1 , LM: ± 2.6, DV: -3.2 mm relative to bregma; -3.3 mm interaural) according to the atlas of Paxinos and Watson (loc. cit.). Rats were given at least 3 days to recover from surgery before starting microdialysis experiments.
Microdialysis
[00135] Microdialysis experiments were performed in the home cage of the animal. A microdialysis probe (MAB 6.14.4.; 4 mm exposed membrane length, polyethersulfone (PES) membrane; MAB, Stockholm, Sweden) was lowered through the guide cannula into the CPu (ventral position of probe tip with reference to the skull: -7.2 mm) ca. 12 hours before the sampling and left in place for the whole testing period.
[00136] The probes were perfused with aCSF at a flow rate of 2 μΙ/min using a CMA 102 perfusion pump (CMA, Solna, Sweden). The composition of the aCSF was 147 mM Na+, 2.7 mM K+, 1.2 mM Ca2+, 0.85 mM Mg2+, 0.04 mM ascorbic acid. The animals were connected by a head block tether system (Instech, Plymouth Meeting, USA) to a dual channel liquid swivel 375/D/22QM (Instech, Plymouth Meeting, USA). Fluorinated ethylene propylene (FEP) tubing and tubing adapters (MAB, Stockholm, Sweden) were used. The sample collection began one hour after start of perfusion with three 20-minutes fractions (baseline). Thereafter, each rat was injected i.p. with (R)- phenylpiracetam and/or L-DOPA (25 mg/kg + benserazide, 15 mg/kg). The samples (40 μΙ) were collected automatically with a fraction collector (CMA/142; CMA, Solna, Sweden) and stored at -20°C until analysis.
Determination of recovery
[00137] To perform in vitro recovery, probes were inserted into a beaker with aCSF (37°C) containing 100 nM solution of (R)-phenylpiracetam or L-DOPA. Five samples (40 μΙ) were collected while only the last 2 were used for analysis of (R)- phenylpiracetam or L-DOPA concentration.
Analytics
[00138] HPLC in combination with atmospheric pressure ionization tandem mass spectrometry (API-MS/MS) was employed (HPLC (Shimadzu Prominence, Duisburg, Germany) coupled to an API 4000 Q Trap (triple quadrupole, Applied Biosystems/MDS Sciex, Darmstadt, Germany) equipped with a Turbolonspray source (ESI)). The analytical column was an Onyx Monolithic C18 50 mm x 2 mm (Phenomenex, Aschaffenburg, Germany). The mobile phase consisted of the eluent A water and eluent B acetonitrile both containing 0.1 % of formic acid. The chromatographic run consisted of a gradient over 1.5 min from 5% acetonitrile in water at start until a mobile phase composition of 50 % acetonitrile in water. A volume of 1 ml was injected in the API/MS/MS. A standard curve was used to calculate sample concentrations of studied agents in our samples.
Results
[00139] The results show that (R)-phenylpiracetam reaches brain levels sufficient to affect primary target (DA carrier). Moreover, when injected together with L-DOPA, there is no pharmacokinetic interaction, i.e. (R)-phenylpiracetam does not affect L- DOPA concentration and L-DOPA does not affect (R)-phenylpiracetam concentrations (see Figures 14 and 15). This shows that interactions observed in behavioural experiments are of pharmacodynamic, not pharmacokinetic nature.
EXAMPLE 4: Effect of (R)-phenylpiracetam on locomotor activity (horizontal
activity) in rats - Fig. 3
Animals
[00140] Experimentally naive adult male Sprague-Dawley rats (230-300 g) are kept four per cage, in a room with controlled temperature (21 ± 1 °C) and humidity. Food and water are available ad libitum and the animals are kept under an alternating 12 h / 12 h day-night cycle (lights on at 07.00) for at least 6 days before the experiments are started. Each animal is used only once. Experimental group consist of 8 animals per group.
Procedure
[00141] Horizontal locomotor activity was measured in 8 perspex boxes (ENV-515- 16, 43.2 cm x 43.2 cm x 30 cm), Med-Associates Inc.) equipped with 4 arrays of 16 infrared photobeams placed 3 cm above the floor. Distance travelled (DT) was used in further analysis as a measure of locomotion.
Treatment
[00142] (R)-Phenylpiracetam was administered i. p. in a volume of 2 ml/kg in saline
Statistical analysis
[00143] Data with locomotor activity were analyzed by means of Kruskal-Wallis ANOVA on ranks followed, if significant, by rank sum test.
Results
[00144] Figure 3 shows that (R)-phenylpiracetam increases locomotor activity (horizontal activity) in rats starting at the dose of 100 mg/kg indicating stimulatory activity.
EXAMPLE 5: Testing of (R)-phenylpiracetam in an electroencephalography
(EEG) screen - Fig. 4
[00145] (R)-Phenylpiracetam was tested at four different concentrations (1 mg/kg, 12.5 mg/kg, 25 mg/kg, and 50 mg/kg) in an EEG screen as described by Dimpfel (Dimpfel, Neuropsychobiology, 58 (2008)178-86).
Animals
[00146] Eight adult Fisher 344 rats (8 months of age, kept on on inverse light-dark cycle, weight about 400 g, provided by Charles River Laboratories, D-97633, Sulzfeld)
were used in this experimental series. Animals were implanted with electrodes into the brain and were given two weeks for recovery from surgery (for details see 6.4). After this the transmitter was plugged in for adaptation and control experiments. During the recording rats were not restricted and could move freely but did not have food available (chewing would have produced too many artifacts).
Acclimatisation and housing conditions
[00147] The animals were allowed to acclimatize for at least 4 weeks before the study started. There was automatic control of light cycle, temperature and humidity. Light hours were 18 h in the evening - 6 h in the morning. Daily monitoring indicated that temperature and humidity remained within the target ranges of 22 ± 2°C and 44 ± 5% respectively. Cages, bedding, and water bottles were changed at regular intervals, i.e. every 2-3 days. Standard diet (Nohrlin H10, Altromin, D-32791 Lage, Germany) was available to the animals ad libitum. The animals had access to domestic quality mains water ad libitum.
Surgery
[00148] Rats were implanted with 4 bipolar concentric steel electrodes within a stereotactic surgical procedure during anaesthesia with ketamine. All four electrodes were placed 3 mm lateral within the left hemisphere. Dorsoventral coordinates were 4, 6, 4.2 and 8 mm and anterior coordinates were 3.7, 9.7, 5.7 and 12.2 mm for frontal cortex, striatum, hippocampus, and reticular formation, respectively (according to the atlas of Paxinos and Watson, 1982). A pre-constructed base plate carrying 4 bipolar stainless steel semi-micro electrodes (neurological electrodes "SNF 100" from Rhodes Medical Instruments, Inc., Summerland, CA 93067, USA) and a 5-pin-plug was fixed to the skull by dental cement interacting with 3 steel screws placed on distance into the bone. The distant recording spot of the electrode was the active electrode whereas the proximal spots of the four electrodes were connected to each other to give a reference. The base plate was carrying a plug to receive later on the transmitter (weight: 5.2 g including battery, 26 mm x 12 mm x 6 mm of size).
Experimental Procedure
[00149] EEG signals were recorded from frontal cortex, hippocampus, striatum and reticular formation of freely moving rats from inside a totally copper shielded room. Signals were wirelessly transmitted by a radio-telemetric system (Rhema Labortechnik, Hofheim, Germany, using 40 MHz as carrier frequency) and were amplified and processed as described earlier to give power spectra of 0.25 Hz resolution (Dimpfel et al. 1986; Dimpfel et al. 1988; Dimpfel et al. 1989; Dimpfel, 2003). In short, after automatic artifact rejection signals were collected in sweeps of 4 s duration and fast- fourier transformed using a Hanning window. Sampling frequency was 512 Hz. Four values were averaged to give a final sampling frequency of 128 Hz, well above the Nyquist frequency. The resulting electrical power spectra were divided into 6 specially defined frequency ranges (delta: 0.8 - 4.5 Hz; theta: 4.75 - 6.75 Hz; alphal : 7.00 - 9.50 Hz; alpha2: 9.75 - 12.50 Hz; betal : 12.75 - 18.50 Hz; beta2: 18.75 - 35.00 Hz). Spectra were averaged in steps of 3 min each and displayed on-line. In an off-line procedure spectra were averaged to give longer periods for further analysis and data presentation.
Test Items
[00150] (R)-Phenylpiracetam was injected i.p. in saline followed by recording of "Tele-Stereo-EEG" intracerebral field potentials in combination with a video tracking system for detection of changes in motility (GJB Datentechnik GmbH, D-98704 Langewiesen, Germany). This system recognized locomotion as well as stereotyped behaviour by following a contrast difference of the black transmitter on the head of the animal in comparison to its environment. The system has been validated in a previous study with different dosages of caffeine.
Treatment Groups
[00151] After surgery all animals were randomly allocated to treatment groups, such that the treatment groups were evenly distributed throughout the caging system. A crossover design with at least one week of drug holidays in between the administrations was used. After a pre-drug period of 45 min for pre-drug recording, drug effects were observed continuously on the screen (artifact control) for 300 min subdivided into 15
min periods after a lag time of 5 min for calming of animals after i.p. administration. Changes of electrical power are expressed as % of the 45 min absolute pre-drug spectral power values within each frequency band.
Statistical Analysis
[00152] Data are expressed as mean values ± S.E.M. Statistics were calculated by means of the Wilcoxon-Mann-Whitney U-test for comparison to results obtained by vehicle injection at the particular time frame. For comparison of data to reference compounds tested earlier under identical conditions discriminant analysis according to Fischer was used. A total of 24 variables (six frequency ranges times 4 brain areas) were used for analysis. Firstly, spherical projection of the results from 47 reference compounds plus physiological sleep was performed using the three spatial coordinates for the first three discriminant axes. Secondly, coding of the result of the fourth to sixth discriminant analysis into red, green and blue was followed by an additive color mixture in analogy to the so-called RGB mode (as used in TV). This matrix of drug actions is kept constant (frozen) for classification of unknown preparations since addition of further compounds would otherwise change the projections.
Results
[00153] (R)-Phenylpiracetam produced a dose dependent attenuation of alpha2 and betal waves. The highest dosage produced a different pattern of changes in that theta power increases within the frontal cortex were observed. Motility was increased. Alpha2 waves are mainly under the control of dopamine (Dimpfel, loc. cit.). Thus, direct or indirect effects on dopaminergic neurotransmission can be expected from (R)- phenylpiracetam. Attenuation of alpha2 and betal waves has also been observed after administration drugs used for treatment of M. Parkinson (Dimpfel and Hoffmann, Neuropsychobiology, 62, 213-20, 2010). In summary (R)-phenylpiracetam shows a profile within the area of stimulatory drugs.
EXAMPLE 6: Effect of (R)-phenylpiracetam in motivation tests - Figs. 5, 6, 7, 8 Test Item
[00154] Methylphenidate purchased from Sigma (Taufkirchen, Germany) was dissolved in distilled water fresh for each test day. Modafinil purchased from Sequoia Research Products Limited (Pangbourne, UK) was dissolved in 1 % w/v methylcellulose (Sigma, Taufkirchen, Germany) in 0.9% NaCI water fresh for each test day. (R)- Phenylpiracetam was dissolved in distilled water fresh for each test day.
Animals
[00155] One hundred and three male Sprague-Dawley rats (Janvier, Le Genest- St-lsle, France) weighing 225-250 g on arrival were used.
Acclimatisation and housing conditions
[00156] The animals were kept under standard laboratory conditions in groups of up to 4 per care with ad libitum access to water. Standard diet for rodents (Altromin) was available to the animals at 15 g per animal/day
Treatment Groups
[00157] Two experiments were performed using an identical protocol. After continuous reinforcement training (CRF) training (see below) all animals were assigned to treatment groups, such that performance across all the groups was similar. The treatment groups were evenly distributed throughout the caging system.
Experimental methods
[00158] In experiment 1 and 2 the following protocols were used:
[00159] Overview: Three tests were performed in a consecutive manner on subsequent days. On day 1-2, animals were habituated individually to Skinner boxes in two sessions, one per day, for 30 min. Animals received "free" food pellets at a random time (one pellet per minute on average). On days 3-8 animals were trained in Skinner
boxes on a continuous reinforcement schedule (one pellet per lever press). On days 9- 10 they were tested in the progressive ratio test (Test 1) off-drug, on days 1 1-12 on- drug. On day 13, a choice test (Test 2) was performed on-drug, on day 14, a consumption test (Test 3) was performed on-drug. Below, tests are described in detail.
Test 1: Progressive ratio (PR) task
[00160] Behavioral testing was conducted in 12 operant test chambers (Med Associates, St. Albans, USA). Each chamber was equipped with a retractable lever, a food dispenser with receptacle, an overhead house light and two stimulus lights, one above the lever and the other above the food receptacle. An infrared photocell beam detected nose pokes into the food receptacle. The apparatus was controlled by a computer system (SmartControl®-lnterface and Med PC-software, Med Associates, St. Albans, USA). The light above the food receptacle indicated the delivery of a food pellet in the receptacle. Rats were first habituated to the operant boxes for two sessions (30 min each) on two consecutive days. Thereafter, animals were trained for six sessions on the CRF schedule for 30 min. Followed by 4 sessions (two session off-drug followed by two sessions on-drug) of an increasing fixed ratio (FR) schedule in steps of 5, with 3 repetitions of each step (i.e. 1-1-1 ; 5-5-5; 10-10-10; ...). When the required FR value of each trial was achieved the light above the food receptacle indicated the delivery of a single food pellet (45 mg, Bioserve, USA). The light remained on until the rat poked its nose in the receptacle. Lever presses while the light was on were counted as perseverative lever presses; they were counted but had no programmed consequences. A session lasted for 90 min or was ended when a rat failed to press the lever for consecutive 10 min. For each session, the value of the last completed ratio (breaking point) was recorded as well as the amount of received rewards, the perseverative lever presses, the duration of the session and the latency to respond. Animals of all treatment groups received respective vehicle/drug infusions 30 min pre-test on the final two sessions involving testing under a PR schedule.
Test 2: Cost-benefit choice test
[00161] In this task the rats had the choice between working for their preferred food (Bioserve pellets) by pressing the lever on a PR schedule as described above or
obtaining lab chow being freely available in a dish (about 15 g) within the operant chamber. The food receptacle and the lever were positioned on the same wall of the operant chamber, the dish containing the lab chow was situated in a corner on the opposite side of the operant chamber. A session lasted for 90 min or ended when a rat failed to press the lever for consecutive 10 min. Thereafter the amount of lab chow ingested was calculated. Animals of all treatment groups received vehicle/drug infusions 30 min p re-test.
Test 3: Consumption test
[00162] The animals were placed individually in separate cages (type III) containing a glass bowls filled with 30 g of pellets. The animals had free access to the reward for 20 min and the amount consumed was measured by subtracting the weight of each glass bowl before the 20 min consumption test and the weight of each glass bowl after the test. Animals of all treatment groups received vehicle/drug infusions 30 min pre-test.
Statisticai Analysis
[00163] The data were subjected to one or two way ANOVAs followed by Dunnett's post hoc test. All statistical computations were carried out with STATISTICS™ (StatSoft®, Tulsa, USA). The level of statistical significance (a-level) was set at p < 0.05.
Results
[00164] Present data show that (R)-phenylpiracetam increases motivation, i.e., the work load, which animals are willing to perform to obtain more rewarding food. At the same time consumption of freely available normal food does not increase. Generally this indicates that (R)-phenylpiracetam increase motivation and in turn effect on mental fatigue would be expected. The effect of (R)-phenylpiracetam is much stronger than that of methylphenidate and amphetamine. Moreover, (S)-phenylpiracetam produces only a very weak effect at 100 mg/kg, which is 2.5 times lower than (R)-phenylpiracetam, and no significant effect at 200 mg/kg.
EXAMPLE 7: Effect of (R)-phenylpiracetam on rats with unilateral SNc lesion
(model of Parkinson's Disease) - Figs. 9, 10
[00165] (R)-Phenylpiracetam was tested in rats with unilateral SNc lesions - a preclinical model of Parkinson's disease. In some experiments it was combined with L- DOPA.In this model, ipsilateral rotations indicate a presynaptic mode of action, which is consistent with inhibition of dopamine uptake as a primary mode of action. L-DOPA produced contralateral rotations.
Animals
[00166] Male Sprague-Dawley rats that have undergone unilateral lesion of medial forebrain bundle using 6-hydroxydopamine and showed a clear-cut ipsilateral rotation bias in amphetamine rotation test. The rats were housed four per cage in the animal room with a controlled 12-hour light-dark cycle and controlled temperature (21 °C) with access to standard laboratory food (chow pellets) and tap water ad libitum. All experiments were carried out between 09:00 and 16:00.
Chemicals
[00167] (R)-Phenylpiracetam was injected i.p. in saline. L-DOPA (25 mg/kg) and benserazide ( 5 mg/kg) were dissolved in saline and injected i.p.
Rotation test
[00168] Rats were injected with substance, placed in Perspex cylinders (30 cm diameter), and the rotational behaviour (360°) was scored for 120 min at 20-min intervals using TSA rotation measurement system.
Statistical analysis
[00169] Data are presented as means +/- SEM. Sums of total scores obtained during a whole recorded period was analysed using two-way ANOVA. If significant, the two-way ANOVA was followed by the Dunnett test for pair-wise multiple comparisons.
Results
[00170] This study showed that (R)-phenylpiracetam increased ipsilateral rotations in a PD animal model. These results suggest that (R)-phenylpiracetam improves fatigue associated with Parkinson's disease and may have also antiparkinsonian activity. In summary, these results suggest that (R)-phenylpiracetam fulfils the criteria of an effective and well-tolerated treatment for PD patients suffering from fatigue and fatigue- associated symptoms, like inactivity, motivational-deficit, apathy, floppiness, exhaustion, lassitude, prostration etc.
[00171] Based on these initial findings, we can conclude that (R)-phenylpiracetam is a candidate for the treatment of fatigue associated with PD due to its effect on the dopamine re-uptake transporter.
EXAMPLE 8: Effect of (R)-phenylpiracetam on L-DOPA-induced dyskinesia - Fig.
11
Animals
[00172] Male Sprague-Dawley rats that underwent stereotaxic lesions of SNc and VTA and reached scores of at least 5.0 net right turns in amphetamine rotation test should be used in this procedure. The animals were housed in a standard laboratory conditions.
Chemicals
[00173] 3,4-Dihydroxy-L-phenylalanine methyl ester (L-DOPA) and benserazide hydrochloride (benserazide) were dissolved in saline (1 ml per 1 kg rat) and applied simultaneously, i.p., at doses of 6 and 15 mg/kg, respectively. The rats were treated
with L-DOPA/benserazide daily, for 19-21 consecutive days until dyskinesia developed. (R)-Phenylpiracetam was injected i.p. in saline.
Rating of abnormal involuntary movements (AIMs)
[00174] Rating of dyskinetic-like movements such as locomotive dyskinesia, limb dyskinesia, axial dystonia, orolingual dyskinesia was scored as described previously and total score was used for the analysis (Dekundy et al., Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. J Neural Transm 1 18, 1703-1716, 201 1 ).
Results
[00175] The data show that (R)-phenylpiracetam does not enhance dyskinesia produced after L-DOPA at the doses, which enhance antiparkinsonian effects of L- DOPA.
EXAMPLE 9: Effect of (R)-phenylpiracetam on sedation induced by reserpine - Fig. 12
Animals
[00176] Male Sprague-Dawley rats weighing ca. 300 g were kept under standard laboratory conditions.
Chemicals
[00177] Animals were injected with reserpine (5 mg/kg) and a-MT (250 mg/kg) 24 and 3.5 h before testing, respectively. (R)-phenylpiracetam (25, 50 or 100 mg/kg) was injected i.p directly before the test.
Locomotor activity in reserpine-treated rats
[00178] The locomotor activity was measured in four perspex boxes (ENV-515-16, 43.2 cm x 43.2 cm x 30 cm), Med-Associates Inc. system) equipped with 4 arrays of 16 infrared photobeams placed 3 cm above the box floor. Distance travelled (DT) was used in further analysis for measuring locomotion. The recording started immediately after placing animals in the open field.
Statistical analysis
[00179] Sums of total scores obtained during a whole recorded period was analysed by one-way ANOVA.
Results
[00180] The data show that (R)-phenylpiracetam attenuates hypokinesia produced by reserpine supporting anti-fatigue and antiparkinsonian activity.
EXAMPLE 10: Effect of (R)-phenylpiracetam on sedation induced by haloperidol - Fig. 13
Animals
[00181] Male Sprague-Dawley rats weighing ca. 300 g were kept under standard laboratory conditions.
Chemicals
[00182] (R)-Phenylpiracetam (25, 50 and 100 mg/kg) was injected i.p. in saline directly before the test. Haloperidol was also given i.p. at the dose of 0.2 mg/kg, 30 min before the test start.
Locomotor activity in haloperidol-treated rats
[00183] . The locomotor activity was measured in four perspex boxes (ENV-515- 16, 43.2 cm x 43.2 cm x 30 cm), Med-Associates Inc. system) equipped with 4 arrays of 16 infrared photobeams placed 3 cm above the box floor. Distance travelled (DT) was used in further analysis for measuring locomotion. The recording started immediately after placing animals in the open field.
Statistical analysis
[00184] Sums of total scores obtained during a whole recorded period were analysed by one-way ANOVA, followed, when significant, by the Holm-Sidak test.
Results
[00185] The data show that (R)-phenylpiracetam dose-dependently attenuates hypokinesia produced by haloperidol supporting anti-fatigue and antiparkinsonian activity (Fig. 13). An additional experiment shows that (S)-phenylpiracetam is much less potent as it produces no effect at 50 mg/kg (Fig. 16A) or an almost negligible effect at 100 mg/kg (Fig. 16B). It should be noted that (R)-phenylpiracetam produced a very robust effect at these doses.
References
Dimpfel, W. (2003). "Preclinical data base of pharmaco-specific rat EEG fingerprints
(tele-stereo-EEG)." Eur J Med Res 8(5): 199-207.
Dimpfel, W., M. Spuler, et al. (1988). "Monitoring of the effects of antidepressant drugs in the freely moving rat by radioelectroencephalography (tele-stereo-EEG)."
Neuropsychobiology 19(2): 1 16-120.
Dimpfel, W., M. Spuler, et al. (1989). "Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG)."
Psychopharmacology (Berl) 98(3): 297-303.
Dimpfel, W., M. Spuler, et al. (1986). "Radioelectroencephalography (Tele-Stereo-EEG) in the rat as a pharmacological model to differentiate the central action of flupirtine from that of opiates, diazepam and phenobarbital." Neuropsychobiology 16(2-3): 163-168.
Krosser, S. and J. Tillner (2007). "Pharmacokinetics of sarizotan after oral administration of single and repeated doses in healthy subjects." International Journal of Clinical Pharmacology and Therapeutics 45: 271-280.
* * * * *
[00186] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
[00187] To the extent possible under the respective patent law, all patents, applications, publications, test methods, literature, and other materials cited herein are hereby incorporated by reference.
Claims
A pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in combination treatment with an agent for dopamine-replacement therapy of Parkinson's disease.
The pharmaceutical composition of claim 1 , wherein said agent is L-DOPA.
The pharmaceutical composition according to claim 1 or 2, wherein the amount of said agent used in said combination treatment is reduced compared to the amount administered in the treatment cycle prior to said combination treatment.
The pharmaceutical composition according to claim 1 or 2, wherein said agent is administered in said combination treatment at a reduced frequency compared to the frequency of administration in the treatment cycle prior to said combination treatment.
The pharmaceutical composition according to claim 4, wherein said agent is L- DOPA, which is administered once daily.
The pharmaceutical composition according to claim 1 or 2, wherein (R)- phenylpiracetam is for use in a treatment comprising the following steps: a. administering (R)-phenylpiracetam to a patient under dopamine- replacement therapy in combination with said agent administered for dopamine-replacement; b. reduction of said agent in daily increments of 10% until signs of Parkinson's symptoms re-emerge; and c. increase of said agent once by 10% compared to the amount of said agent last administered according to step b.; and d. continuation of the combination treatment using (R)-phenylpiracetam and the amount of said agent used in accordance with step c.
7. The pharmaceutical composition according to claim 6, wherein said steps are performed in order to establish said combination treatment.
8. The pharmaceutical composition according to claim 6, wherein said steps are performed in order to improve an established combination treatment.
9. A pharmaceutical composition comprising (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof for use in the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
10. The pharmaceutical composition according to any one of claims 1 to 9, wherein (R)- phenylpiracetam is present as (R)-phenylpiracetam hydrochloride.
11. The pharmaceutical composition according to any one of claims 1 to 10, wherein (R)-phenylpiracetam is for administration in a range from about 1 mg to about 250 mg/day, or in a range from about 25 mg to about 200 mg/day, or in a range from about 50 mg to about 150 mg/day.
12. The pharmaceutical composition according to any of the preceding claims, wherein (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration once a day, twice a day, or three times a day.
13. The pharmaceutical composition according to any of the preceding claims, wherein (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in an oral formulation.
14. The pharmaceutical composition according to any of the preceding claims, wherein (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in combination with at least one additional pharmaceutical agent which has been shown to be effective for the treatment of Parkinson's disease.
15. The pharmaceutical composition according to claim 14, wherein said at least one additional pharmaceutical agent is selected from: L-DOPA, carbidopa, other types of dopamine agonists, including eltoprazine, MAO-inhibitors, COMT inhibitors, and benserazide.
16. The pharmaceutical composition according to any of the preceding claims, wherein (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in combination with at least one additional pharmaceutical agent which has been shown to be effective for the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
17. The pharmaceutical composition according to claim 16, wherein said at least one additional pharmaceutical agent is selected from: rasagiline and pramipexole.
18. A method of improving the dopamine-replacement therapy of Parkinson's disease and/or of treating fatigue, particularly mental fatigue, associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof.
19. The method of claim 18, wherein said agent is L-DOPA.
20. The method according to claim 18 or 19, wherein the amount of said agent used in said combination treatment is reduced compared to the amount administered in the treatment cycle prior to said combination treatment.
21. The method according to claim 18 or 19, wherein said agent is administered in said combination treatment at a reduced frequency compared to the frequency of administration in the treatment cycle prior to said combination treatment.
22. The method according to claim 21 , wherein said agent is L-DOPA, which is administered once daily.
23. The method according to claim 18 or 19, wherein (R)-phenylpiracetam is for use in a treatment comprising the following steps: a. administering (R)-phenylpiracetam to a patient under dopamine- replacement therapy in combination with said agent administered for dopamine-replacement; b. reduction of said agent in daily increments of 10% until signs of Parkinson's symptoms re-emerge; and
c. increase of said agent once by 10% compared to the amount of said agent last administered according to step b.; and d. continuation of the combination treatment using (R)-phenylpiracetam and the amount of said agent used in accordance with step c.
24. The method according to claim 23, wherein said steps are performed in order to establish said combination treatment.
25. The method according to claim 23, wherein said steps are performed in order to improve an established combination treatment.
26. A method of treating fatigue associated with Parkinson's disease in a subject in need thereof, comprising the step of administering an effective amount of (R)- phenylpiracetam or a pharmaceutically acceptable salt thereof..
27. The method according to any one of claims 18 to 26, wherein (R)-phenylpiracetam is present as (R)-phenylpiracetam hydrochloride.
28. The method according to any one of claims 18 to 27, wherein (R)-phenylpiracetam is for administration in a range from about 1 mg to about 250 mg/day, or in a range from about 25 mg to about 200 mg/day, or in a range from about 50 mg to about 150 mg/day.
29. The method according to any of the preceding claims, wherein (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration once a day, twice a day, or three times a day.
30. The method according to any of the preceding claims, wherein (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in an oral formulation.
31. The method according to any of the preceding claims, wherein (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in combination with at least one additional pharmaceutical agent which has been shown to be effective for the treatment of Parkinson's disease.
32. The method according to claim 31 , wherein said at least one additional pharmaceutical agent is selected from: L-DOPA, carbidopa, other types of dopamine agonists, including eltoprazine, MAO-inhibitors, COMT inhibitors, and benserazide.
33. The method according to any of the preceding claims, wherein (R)-phenylpiracetam or a pharmaceutically acceptable salt thereof is for administration in combination with at least one additional pharmaceutical agent which has been shown to be effective for the treatment of fatigue, particularly mental fatigue, associated with Parkinson's disease.
34. The method according to claim 33, wherein said at least one additional pharmaceutical agent is selected from: rasagiline and pramipexole.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261668076P | 2012-07-05 | 2012-07-05 | |
EP12004986 | 2012-07-05 | ||
EP12004986.1 | 2012-07-05 | ||
US61/668,076 | 2012-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014005721A1 true WO2014005721A1 (en) | 2014-01-09 |
Family
ID=49881370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/001991 WO2014005721A1 (en) | 2012-07-05 | 2013-07-05 | Use of (r)-phenylpiracetam for the treatment of parkinson's disease |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW201408294A (en) |
WO (1) | WO2014005721A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2891491A1 (en) * | 2014-01-03 | 2015-07-08 | Merz Pharma GmbH & Co. KGaA | Use of (r)-phenylpiracetam for the treatment of sleep disorders |
WO2015173763A1 (en) * | 2014-05-14 | 2015-11-19 | Akciju Sabiedriba "Olainfarm" | Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001062726A2 (en) * | 2000-02-23 | 2001-08-30 | Ucb, S.A. | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
WO2007104780A2 (en) | 2006-03-16 | 2007-09-20 | Akciju Sabiedriba 'olainfarm' | N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use |
WO2010015029A1 (en) * | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
EP2193794A1 (en) * | 2008-12-05 | 2010-06-09 | Merz Pharma GmbH & Co. KGaA | Use of eltoprazine for the treatment of L-Dopa-induced dyskinesia |
-
2013
- 2013-07-03 TW TW102123815A patent/TW201408294A/en unknown
- 2013-07-05 WO PCT/EP2013/001991 patent/WO2014005721A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001062726A2 (en) * | 2000-02-23 | 2001-08-30 | Ucb, S.A. | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
WO2007104780A2 (en) | 2006-03-16 | 2007-09-20 | Akciju Sabiedriba 'olainfarm' | N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use |
WO2010015029A1 (en) * | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
EP2193794A1 (en) * | 2008-12-05 | 2010-06-09 | Merz Pharma GmbH & Co. KGaA | Use of eltoprazine for the treatment of L-Dopa-induced dyskinesia |
Non-Patent Citations (43)
Title |
---|
A.R. GENNARO: "Remington's Pharmaceutical Sciences" |
AKHAPKINA ET AL., ATMOSFERA. NERVNYE BOLEZNI, vol. 3, 2004, pages 28 - 31 |
BEISKE ET AL., MOV DISORD., vol. 25, 2010, pages 2456 - 60 |
BEISKE; SVENSSON, ACTA NEUROL SCAND, vol. 190, 2010, pages 78 - 81 |
BEL'SKAIA ET AL., ZH NEVROL PSIKHIATR IM S S KORSAKOVA., vol. 107, 2007, pages 40 - 43 |
BOBKOV ET AL., BIULL EKSP BIOL MED., vol. 95, 1983, pages 50 - 53 |
BROWN R G ET AL: "The Parkinson fatigue scale", PARKINSONISM AND RELATED DISORDERS, ELSEVIER SCIENCE, OXFORD, GB, vol. 11, no. 1, 1 January 2005 (2005-01-01), pages 49 - 55, XP027741541, ISSN: 1353-8020, [retrieved on 20050101] * |
BROWN RG ET AL., PARKINSONISM RELATED DISORDERS, vol. 11, 2005, pages 49 - 55 |
CHAUDHURI; BEHAN, J NEUROL SCI., vol. 179, no. 1-2, 2000, pages 34 - 42 |
CHAUDHURI; BEHAN, LANCET, vol. 363, 2004, pages 978 - 88 |
DIMPFEL, NEUROPSYCHOBIOLOGY, vol. 58, 2008, pages 178 - 86 |
DIMPFEL, W.: "Preclinical data base of pharmaco-specific rat EEG fingerprints (tele-stereo-EEG", EUR J MED RES, vol. 8, no. 5, 2003, pages 199 - 207 |
DIMPFEL, W.; M. SPULER ET AL.: "Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG", PSYCHOPHARMACOLOGY (BERL, vol. 98, no. 3, 1989, pages 297 - 303 |
DIMPFEL, W.; M. SPULER ET AL.: "Monitoring of the effects of antidepressant drugs in the freely moving rat by radioelectroencephalography (tele-stereo-EEG", NEUROPSYCHOBIOLOGY, vol. 19, no. 2, 1988, pages 116 - 120 |
DIMPFEL, W.; M. SPULER ET AL.: "Radioelectroencephalography (Tele-Stereo-EEG) in the rat as a pharmacological model to differentiate the central action of flupirtine from that of opiates, diazepam and phenobarbital", NEUROPSYCHOBIOLOGY, vol. 16, no. 2-3, 1986, pages 163 - 168 |
DIMPFEL; HOFFMANN, NEUROPSYCHOBIOLOGY, vol. 62, 2010, pages 213 - 20 |
FRIEDMAN JH ET AL., MOV. DISORDERS, vol. 25, 2010, pages 805 - 822 |
GALLAGHER ET AL., MOV DISORD., vol. 25, 2010, pages 2493 - 2500 |
GERASIMOVA ET AL., ZH NEVROL PSIKHIATR IM S S KORSAKOVA, vol. 105, 2005, pages 63 - 64 |
GUSTOV ET AL., ZH NEVROL PSIKHIATR IM S S KORSAKOVA, vol. 106, 2006, pages 52 - 53 |
HAVLIKOVA ET AL., EUR J NEUROL., vol. 15, 2008, pages 475 - 80 |
HAVLIKOVA ET AL., J NEUROL SCI., vol. 270, 2008, pages 107 - 113 |
HAVLIKOVA ET AL., PARKINSONISM RELAT DISORD., vol. 14, 2008, pages 187 - 192 |
KALINSKIJ; NAZAROV, ZH NEVROL PSIKHIATR 1M S S KORSAKOVA, vol. 107, 2007, pages 61 - 63 |
KALINSKIJ; NAZAROV, ZH NEVROL PSIKHIATR 1M SS KORSAKOVA, vol. 107, 2007, pages 61 - 63 |
KARABANOV ET AL., ATMOSFERA. NERVNYE BOLEZNI, vol. 4, 2009, pages 29 - 32 |
KOLESNIKOVA, O.A; VASILYEV, Y.N., PROGRESS OF MODERN NATURAL SCIENCES, 2008, pages 45 - 46 |
KR6SSER, S.; J. TILLNER: "Pharmacokinetics of sarizotan after oral administration of single and repeated doses in healthy subjects", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 45, 2007, pages 271 - 280 |
KRUPP ET AL., ARCH NEUROL., vol. 46, 1989, pages 1121 - 1123 |
LYBZIKOVA ET AL., ZH NEVROL PSIKHIATR 1M S S KORSAKOVA., vol. 108, 2008, pages 69 - 70 |
MALYKH ANDREI G ET AL: "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders", DRUGS : INTERNAT. JOURNAL OF CURRENT THERAPEUTICS AND APPLIED PHARMACOLOGY REVIEWS, FEATURING EVALUATIONS ON NEW DRUGS AND DRUG THERAPY, AND DRUG LITERATURE ABSTRACTS, WOLTERS KLUWER HEALTH ADIS, AUSTRALIA, vol. 70, no. 3, 1 January 2010 (2010-01-01), pages 287 - 312, XP009162620, ISSN: 0012-6667 * |
MENDONCA ET AL., MOV. DISORD., vol. 22, 2007, pages 2070 - 2076 |
MORITA AKIHIKO ET AL: "Pramipexole Reduces the Prevalence of Fatigue in Patients with Parkinson's Disease", INTERNAL MEDICINE (TOKYO), vol. 50, no. 19, 2011, pages 2163 - 2168, XP002688676 * |
MORITA ET AL., INTERN MED., vol. 50, 2011, pages 2163 - 2168 |
NOVIKOVA ET AL., STOMATOLOGIIA (MOSK, vol. 87, 2008, pages 41 - 45 |
OLIVIER RASCOL: "A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecifi ed and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes", 7 April 2011 (2011-04-07), XP055046322, Retrieved from the Internet <URL:http://ac.els-cdn.com/S1474442211700734/1-s2.0-S1474442211700734-main.pdf?_tid=ce3cf428-3d3e-11e2-af06-00000aab0f01&acdnat=1354535253_379ce207ffa1d143f20b3614e9683135> [retrieved on 20121203], DOI: 10.1016/S1474- * |
RASCOL ET AL., LANCET NEUROL., vol. 10, 2011, pages 415 - 23 |
SAVCHENKO ET AL., ZH NEVROL PSIKHIATR 1M S S KORSAKOVA, vol. 105, 2005, pages 22 - 26 |
TIURENKOV ET AL., EKSP KLIN FARMAKOL., vol. 70, 2007, pages 24 - 29 |
VASILIEV, Y.N.; GRIGORJEVA, N.A., SIBERIAN MEDICAL MAGAZINE, 2009 |
VASILYEV, Y.N.; KOLESNIKOVA, O.A., CURRENT ISSUES OF EXPERIMENTAL AND CLINICAL MEDICINE, 20 December 2008 (2008-12-20) |
YU YU FIRSTOVA ET AL: "The effects of scopolamine and the nootropic drug phenotropil on rat brain neurotransmitter receptors during testing of the conditioned passive avoidance task", NEUROCHEMICAL JOURNAL, SP MAIK NAUKA/INTERPERIODICA, DORDRECHT, vol. 5, no. 2, 8 June 2011 (2011-06-08), pages 115 - 125, XP019913303, ISSN: 1819-7132, DOI: 10.1134/S1819712411020048 * |
ZVEJNIECE ET AL., BASIC CLIN PHARMACOL TOXICOL., vol. 109, 2011, pages 407 - 412 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2891491A1 (en) * | 2014-01-03 | 2015-07-08 | Merz Pharma GmbH & Co. KGaA | Use of (r)-phenylpiracetam for the treatment of sleep disorders |
WO2015173763A1 (en) * | 2014-05-14 | 2015-11-19 | Akciju Sabiedriba "Olainfarm" | Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase |
EA030563B1 (en) * | 2014-05-14 | 2018-08-31 | Акционерное Общество "Олайнфарм" | Pharmaceutical composition for the prevention and treatment of peripheral neuropathy |
Also Published As
Publication number | Publication date |
---|---|
TW201408294A (en) | 2014-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20100014392A (en) | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia | |
KR101754045B1 (en) | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug | |
CA2766282C (en) | Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue | |
KR20160111013A (en) | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | |
KR20140146207A (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
AU2014393490B2 (en) | (S)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
IL168853A (en) | Use of barbituric acid derivatives in the preparation of a medicament for treating movement disorders | |
WO2021222342A1 (en) | Methods of use of t-type calcium channel modulators | |
KR102232198B1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
WO2014005721A1 (en) | Use of (r)-phenylpiracetam for the treatment of parkinson's disease | |
EP3409275B1 (en) | Composition for prevention and/or treatment of diseases associated to hyperalgesia | |
TW201609640A (en) | Use of indolyl and indolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits | |
WO2014005720A1 (en) | Use of (r)-phenylpiracetam for the treatment of disease-associated fatigue | |
US11660279B2 (en) | Therapeutic agents for treating restless leg syndrome | |
US11033521B2 (en) | Levodopa fractionated dose composition and use | |
US20140080847A1 (en) | Compositions and Methods for Affecting Energy Balance, Body Composition, Fitness, and Well-Being | |
AU2013245675B2 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent | |
CN112691102A (en) | Application of baicalein in preventing and treating Parkinson's disease/Parkinson's syndrome depression symptoms | |
JPH09500375A (en) | Use of efaroxan and its derivatives for the manufacture of a medicament for the treatment of Parkinson's disease | |
US20230390216A1 (en) | Bromhexine for the treatment of pain | |
WO2016209765A1 (en) | Combination medication for neuro-degenerative diseases | |
EP2891491A1 (en) | Use of (r)-phenylpiracetam for the treatment of sleep disorders | |
CA3205858A1 (en) | Methods of treating mental or mood disorders using 2-bromo-lsd | |
KR20220159282A (en) | Modified herbal compositions for neuromodulation | |
CN111491627A (en) | Use of benzoic acid or salts and derivatives thereof for preventing or treating melancholia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13734671 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13734671 Country of ref document: EP Kind code of ref document: A1 |